Coordination Chemistry Reviews 379 (2019) 99-120

Contents lists available at ScienceDirect

Coordination Chemistry Reviews

journal homepage: www.elsevier.com/locate/ccr

Metalloporphyrin nanoparticles: Coordinating diverse theranostic functions

Shuai Shao^a, Venugopal Rajendiran^{a,b}, Jonathan F. Lovell^{a,*}

^a Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA ^b Department of Chemistry, School of Basic and Applied Sciences, Central University of Tamil Nadu, Thiruvarur 610 005, India

ARTICLE INFO

Article history: Received 26 July 2017 Received in revised form 3 September 2017 Accepted 3 September 2017 Available online 22 September 2017

Keywords: Metalloporphyrins Nanoparticles Theranostics

ABSTRACT

Metalloporphyrins serve key roles in natural biological processes and also have demonstrated utility for biomedical applications. They can be encapsulated or grafted in conventional nanoparticles or can selfassemble themselves at the nanoscale. A wide range of metals can be stably chelated either before or after porphyrin nanoparticle formation, without the necessity of any additional chelator chemistry. The addition of metals can substantially alter a range of behaviors such as modulating phototherapeutic efficacy; conferring responsiveness to biological stimuli; or providing contrast for magnetic resonance, positron emission or surface enhanced Raman imaging. Chelated metals can also provide a convenient handle for bioconjugation with other molecules via axial coordination. This review provides an overview of some recent biomedical, nanoparticulate approaches involving gain-of-function metalloporphyrins and related molecules.

© 2017 Elsevier B.V. All rights reserved.

Contents

| 1. | Introd | duction |
|----|--------|---|
| | 1.1. | Metalloporphyrins in nature |
| | 1.2. | Nanoparticles in biomedicine |
| 2. | Prepa | aration of metalloporphyrin nanoparticles |
| | 2.1. | Coordination chemistry |
| | 2.2. | Incorporation of metalloporphyrins in nanoparticles |
| | | 2.2.1. Solvent mixing |
| | | 2.2.2. Surface attachment |
| | | 2.2.3. Liposome encapsulation |
| | | 2.2.4. Dendrimers |
| 3. | Biom | edical applications of metalloporphyrin nanoparticles |
| | 3.1. | Magnetic resonance imaging (MRI) |
| | 3.2. | Positron emission tomography (PET) |
| | 3.3. | Optical imaging |
| | | 3.3.1. Surface enhanced Raman scattering (SERS) |
| | | 3.3.2. Photoacoustic contrast |
| | | 3.3.3. Upconversion sensitizer |
| | 3.4. | Photodynamic therapy (PDT) agents |
| | 3.5. | Axial coordination |
| | 3.6 | Superoxide dismutase (SOD) mimicking agents |

Abbreviations: AuNP, gold nanoparticle; Dox, doxorubicin; EPR, enhanced permeability and retention; MRI, magnetic resonance imaging; PDT, photodynamic therapy; PEG, polyethylene glycol; PET, positron emission tomography; PS, photosensitizer; ROS, reactive oxygen species; SERS, surface enhance Raman scattering; SOD, superoxide dismutase; UCL, upconversion luminescence; UCNP, upconversion nanoparticles.

Corresponding author.

E-mail address: jflovell@buffalo.edu (J.F. Lovell).



Review





| | 3.7. Oxygen sensing | . 117 |
|----|---------------------|-------|
| 4. | Conclusions. | 118 |
| | Acknowledgements | 118 |
| | References | 118 |
| | | |

1. Introduction

Porphyrins and related molecules are well-suited for theranostic applications [1–5]. Metalloporphyrins have unique chemical properties which confer distinct bioinorganic function. Bevond roles in natural bioprocesses, metalloporphyrins can be used for biomedical applications. As shown in Fig. 1, by adding different metals, new capabilities can be conferred by the metal. For example, Mn- and Gd-porphyrin have been applied as magnetic resonance imaging (MRI) contrast agents; ⁶⁴Cu-porphyrin has been demonstrated as an efficient positron emission tomography (PET) agent; Mn-, Ni- and Fe-porphyrins show potential for use in surface enhanced Raman scattering (SERS); Pd- and Pt-porphyrin have been used as photosensitizers for upconversion nanoparticles (UCNPs), as well as components for optical oxygen sensors; Znand Al-porphyrin have been used for photodynamic therapy (PDT); Mn- and Fe-porphyrin have been used as superoxide dismutase (SOD) mimicking agents; Co-, Sn- and Si-porphyrin are able to participate in bioconjugation by axial coordination ligands. This review provides an overview of some of these unique nanoscale applications of metalloporphyrins.

1.1. Metalloporphyrins in nature

The Fe²⁺ containing heme group (Fig. 2A), is not just the oxygen carrier found in hemoglobin; it is a cofactor of hemeproteins including cytochromes and peroxidases that carry out diverse biological reactions. Through shuttling electrons, these iron porphyrins catalyze oxidation and reduction reactions. Cytochrome P450, one of the most important heme enzymes, was so-named

when an unexpected pigment was observed with 420 nm absorbance in microsomes during reduction in the presence of carbon monoxide [6]. The pigment was later recognized specifically as a hemeprotein in 1964 [7]. Cytochrome P450 is a crucial component for catalyzing the hydroxylation of organic substrates [8]. Heme dependent peroxidases are another important group of hemeproteins, composed of single polypeptide chains with a heme complex attached by the chelation between iron and histidine, that catalyzes the breakdown of hydrogen peroxide [9].

Occurring in most plants and algae, photosynthesis converts light energy into chemical energy and is the primary source of biological energy and molecular oxygen on earth. Chlorophyll, a family of green pigments that absorb sunlight, is central to photosynthesis. It chelates a magnesium atom center (Fig. 2B). Chlorophyll is a reduced porphyrin (chlorin) macrocycle, which contains two π electrons less than porphyrin. Chlorophyll is intensely studied in biological, environmental, and agricultural, and plant sciences [10–13].

Another metal pyrrole-like macrocycle is Vitamin B_{12} , a crucial vitamin for nervous system function (Fig. 2C). It contains a cobalt atom in the center of the aromatic tetrapyrrole. Vitamin B12 is necessary for the function of methionine synthase and L-methylmalonyl coenzyme A mutase. Vitamin B12 deficiency results in megaloblastic anemia and nervous system disease [14–17]. Sea food and meat are good dietary sources of vitamin B12.

Methane is the simplest organic compound and a potential clean energy source. Methane-producing archaea produce nearly 1 billion metric tons of methane annually in the global carbon cycle [18]. Cofactor F430, a nickel-containing tetrapyrrole (Fig. 2D), is found in methyl-coenzyme M reductase (MCR) and catalyzes the



Fig. 1. Illustrative biomedical applications of porphyrins enabled via the coordination of different metals in the core of the macrocycle.



Fig. 2. Examples of natural metalloporphyrins. (A) Heme B, an iron(II)-porphyrin compound in red blood cells, participates in the transportation of oxygen. (B) Chlorophyll a, a magnesium chlorin, plays a crucial role in photosynthesis. (C) Methylcobalamin (vitamin B12), a vitamin required for nervous system function. (D) Cofactor F430 catalyzes methanogenesis in methanogenic archaea.

terminal step of methanogenesis. The successful biosynthesis of F430 was achieved recently and holds potential for industrial metabolic bioenergetic engineering [19].

1.2. Nanoparticles in biomedicine

Nanoparticles hold promise for many biomedical applications [20-23]. Intravenous administration of pharmaceutical suspensions was historically avoided, given the risk of embolism, but clinical colloidal drug delivery approaches have been made possible by suitable nanoparticles, like liposomes and micelles [24]. Compared to small molecules, nanoparticles can improve drug efficiency via prolonging circulation times and reducing toxicity [25]. For some diseases like cancer, nanoparticles can accumulate in tumors due to the enhanced permeability and retention (EPR) effect [26–29]. Nanoparticles can act as efficient transport vehicles for drugs or functional molecules with potential for high loading capacity and tunable chemical and biological stability [30-33]. The high surface-to-volume ratios of most nanoparticles allow for productive surface modification by grafting biomolecules such as targeting ligands or detection probes [34]. These intrinsic properties motivate the development and design of nanoparticles as theranostic agents capable of multiple functions, such as optical imaging, bio-sensing, ligand targeting, and delivery of drugs.

2. Preparation of metalloporphyrin nanoparticles

2.1. Coordination chemistry

Tetrapyrroles are versatile functional molecules that have found applications in chemistry, biology, medicine, and materials science [35]. As mentioned above, metals play a central role in many naturally occurring porphyrins, highlighting the significance of bioinorganic coordination chemistry. Coordination of metals in the porphyrin can enhance the stabilization of the ring, thereby promoting a more planar conformation [36] or enhance thermodynamic and kinetic stability [37,38]. The photochemical and photophysical properties of the porphyrin can be altered by the nature of the metal atom coordinated in the porphyrin ring. Porphyrins and many of their derivatives readily form N-ligated complexes with a variety of metals by deprotonation of one or two of the pyrrole NH protons via the formation of σ bonds, either within the core or above it [39]. The nature of the bonds and orbital overlap between metal ions and the porphyrin ligand have been comprehensively reviewed [40]. Generally, σ -complexes of porphyrins are known for almost every metal cation in the periodic table. In addition to σ -complexes, a considerable number of π -complexes derived from tetrapyrrolic ligands have been recently reported [41]. This review discusses coordination chemistry of σ -complexes, especially transition metal complexes because these have been studied more frequently in metalloporphyrin nanoparticles.

When 2 protons are lost, the porphyrin core forms a dianion that acts as a tetradentate ligand, so chelated metal ions usually have a coordination number of at least 4 [42]. Importantly, π electronic delocalization, which occurs within the porphinato ligand, leads to planarity of the macrocycle and an essentially square-planar environment for the metal ion in the four-coordinate complexes. Upon addition of other ligands in addition to four coordinate metalloporphinato core, there is a possibility of forming 4–8 higher coordination number (C.N) metalloporphyrins. The geometries of square-planar (C.N = 4), square-pyramidal (C.N = 5) and octahedral (C.N = 6) metalloporphyrins are shown in Scheme 1 [42,43]. In general, the geometry of transition metal complexes



Scheme 1. Different possible coordination geometries of metalloporpyrins. Ct = center of the ring, L = axial ligand, 4N = porphinato core, M = metal ion. Used with permission from Refs. [42,43]. Copyright, American Chemical Society.



Fig. 3. Examples of metalloporphyrin nanoparticle preparation. (A) Solvent mixing to form polymeric metalloporphyrin nanoparticles. (B) Grafting metalloporphyrins to existing nanoparticles via either covalent binding or chelation. (C) Liposomal formulation of metalloporphyrins; hydrophilic and hydrophobic metalloporphyrin are encapsulated in the liposome core or within the lipid bilayer, respectively. (D) Structures of different types of metalloporphyrin dendrimers. Metalloporphyrins can occupy the cores, branch nodes, terminal nodes or all nodes.

depends on the electronic configuration of the d orbital of the coordinating metal ion. In the case of four-, five- and six-coordinated first-row transition metalloporphyrins, the influence of occupied or unoccupied $3d_{xy}^2$ and $3d_z^2$ orbitals on the bond distances of M–N and M–L is significant [42]. Relatively large M–N bond distances are observed in the case of five-coordinated metalloporphyrins compared to four and six-coordinated metalloporphyrins due to displacement of the metal atom out of the porphinato plane [42]. Other properties are also relevant besides metalloporphyrin geometry. The periodic table of metalloporphyrins, synthesis, selected metal insertion procedures, role of the metal oxidation state in the carrier, the stable oxidation states of metal ions in metalloporphyrins and optical absorption spectra are all other considerations [44]. Apart from transition metal-based metalloporphyrins, non-metallic and semi-metallic elements are also able to be chelated [45]. This includes boron and tellurium porphyrins complexes, and Group 14 (silicon and tin) and Group 15 porphyrin complexes.

2.2. Incorporation of metalloporphyrins in nanoparticles

Typically, chelation of metals in the porphyrin is completed prior to nanoparticle formation, although this need not be the case. In some uses, like ⁶⁴Cu PET imaging, post-chelation is advantageous due to the limited half-life of the radionuclide. There are other advantages of post-chelation approaches, since if chelation is possible without degradation of the nanoparticles, one single batch of nanoparticles can be divided and chelated with various metals to confer multiple functions. Metalloporphyrins can attach to the nanoparticle carrier either as encapsulated cargo or via surface modification. In this section, some common methods to prepare metalloporphyrin nanoparticles are briefly discussed.

2.2.1. Solvent mixing

Similar to freebase porphyrins, many metalloporphyrins and derivatives are hydrophobic and soluble only in organic solvents. For the mixing solvent method, sometimes involving host-guest methods, the first step is dissolving hydrophobic metalloporphyrins (and possibly stabilizers) in organic solvents which are miscible with water such as methanol, acetonitrile, or dimethyl sulfoxide. Addition of water, which may contain surfactants, leads to colloidal self-assembly that prevents the hydrophobic metalloporphyrin core from aggregation. The organic solvents can subsequently be removed by dialysis and the final metalloporphyrin nanoparticles are transferred to a fully aqueous solution (Fig. 3A) [46,47]. If the nanoparticles are dense enough, they may be collected through centrifugation. By cross-linking metalloporphyrin cores to the polymer matrix, the thermal stability of the nanoparticles could be improved [48]. The size and polydispersity of the obtained nanoparticles depends on the types of metalloporphyrin, the selection of surfactants, the ratio between host and guest solvents, and the reaction temperature [46,47]. There are many possible selections for matrix polymers, such as (polyethylene)glycol (PEG), poly(methyl vinyl ether-co-maleic anhydride) (PVM/MA), chitosan derivatives and surfactants like Tween and Pluronic. The solvent mixing method is a convenient method to form metalloporphyrin nanoparticles. However, the process might result in leakage of metalloporphyrins from the matrix in biological settings and may be difficult to accurately control particle size and polydispersity.

2.2.2. Surface attachment

Covalent conjugation techniques can use routine chemistry such as amide functionalization, which for example can be implemented if the surface of nanoparticles are modified with amine groups and the metalloporphyrin contains carboxylic acid groups, or vice versa [49,50]. Non-covalent binding to nanoparticles is another strategy. Surfaces of the nanoparticles provide capacity to adsorb metalloporphyrins. Some drug delivery systems have used this approach to design metalloporphyrin nanostructures with specific features, like pH sensitivity [51] or specific electron coupling effect [52]. Mesoporous silica nanoparticles (MSNP) are a versatile system for cargo delivery through physical absorption. The high surface area and pore volume allows good loading efficiency. Besides weak electrostatic interactions, surface modification enables control of drug release during intracellular uptake or by external stimuli [53] (Fig. 3B).

2.2.3. Liposome encapsulation

Liposomes are frequently used as nanocarriers. Water-soluble metalloporphyrins can be passively loaded in the liposome aqueous core. Metalloporphyrins with poor water solubility can be loaded within the bilayer (Fig. 3C). However, loading efficiency

and stability could be problematic and hydrophobic metalloporphyrins could induce over-saturated packing structure and decreased stability, especially in biological conditions. To enhance performance of liposome-loaded porphyrins, unique amphiphiles like metalloporphyrin-phospholipids have been developed. Instead of encapsulating the cargo into the liposome core or bilayer, metalloporphyrin can be pre-conjugated directly to a phospholipid side chain. In this way, the metalloporphyrin lipid self-assembles to form a lipid-like bilayer structure [54–56].

2.2.4. Dendrimers

Metalloporphyrins can be incorporated into dendrimer nanoparticles, the size of which can be precisely controlled by stepwise iterative synthesis. The structures of four different types of metalloporphyrin dendrimers are shown in Fig. 3D. Metalloporphyrins may form the core, the branch nodes, the branch terminal nodes or both the core and every node. Metalloporphyrin-cored dendrimers can be synthesized through divergent or convergent approaches. In the divergent strategy, the metalloporphyrin core is the starting point of the architecture, and branches are extended layer by layer. However, this often leads to structural imperfections in the final product. The convergent strategy pre-assembles the dendrons before attachment to the metalloporphyrin cores [57]. Metalloporphyrin dendrimers can also be combined with block copolymers [58].

3. Biomedical applications of metalloporphyrin nanoparticles

3.1. Magnetic resonance imaging (MRI)

Since the first MR images of human body were demonstrated several decades ago, MRI has become an indispensable noninvasive diagnostic imaging technology [59]. T1 relaxation time, also known as the spin–lattice relaxation time, tends to be more important for paramagnetic contrast agents containing manganese or gadolinium, although these paramagnetic metals reduce both T1 and T2 relaxation times. The T2 relaxation time, also known as the spin–spin relaxation time, is a more relevant signal for super-paramagnetic agents, especially iron oxide nanoparticles.

Due to the stable chelation, metalloporphyrins reduce risk of transmetallation which can cause fibrosis disorders or neurotoxicity [60,61]. Mn(II), carrying 5 unpaired electrons and Gd(III), carrying 7 unpaired electrons, are commonly used in T1-weighted MR contrast imaging. In porphyrins, the distance between the two diagonal N is 2.9 Å. For Gd³⁺, its ionic radius of 1.08 Å plus the Gd–N average bond length of 2.6 Å results in a small N–Gd–N angle, which causes higher distress and instability to the whole complex. Comparatively, Mn(II) and Mn(III) display an ionic radius of 0.6–0.7 Å and an Mn–N average bond length of 2 Å indicating a more stable planar complex [62–65].

In the past 20 years, numerous studies have reported Mnporphyrins as MRI contrast agents [66–68]. Both Mn(III)porphyrin (7.4 mM⁻¹ s⁻¹) and Mn(III)-porphyrin conjugated dextrans (8.9 mM⁻¹ s⁻¹) showed a higher longitudinal relaxivity (R1) than an existing MRI agent Gd-DTPA (5.1 mM⁻¹ s⁻¹), low cytotoxicity and specific binding to tumor cell membranes [69].

Pan et al. developed a self-assembled nanobialys which was labeled with Mn(III)-porphyrin as an MR contrast agent (Fig. 4A) [70]. The "bialy" nanostructure, with tunable particle size and low polydispersity, had good stability. Mn(III)-porphyrin was encapsulated in the polymeric inverted-micelle by a phase transfer process. With the addition of biotin, this toroidal-shaped nanoparticle efficiently targeted fibrin, a component of intravascular thrombosis, and offered site-specific MR T1-weighted imaging of the clot (Fig. 4B). Additionally, nanobialys showed more than 98% drug loading efficiency and more than 80% drug retention.



Fig. 4. Self-assembled nanobialys. (A) The structure of Mn(III) porphyrin nanobialys. Mn(III) porphyrin provided MRI contrast. (B) MRI of fibrin-targeted nanobialys (1) (right) or control group with biotin and no metal (6) (left), or no biotin with metal (5) (middle) bound to cylindrical plasma clots measured at 3.0 T. Permission obtained from Ref. [70]. Copyright (2008) by the American Chemical Society.



Fig. 5. Mn-porphyrin, PLA-coated Au nanoshells. (A) DOX@PLA@Au-PEG-MnP NPs. Mn-porphyrin was grafted on the surface for MRI contrast. (B) T1-weighted images of DOX@PLA@Au-PEG-MnP NPs at different concentrations at 0.5 T, 37 °C. In vivo T1-weighted images before injection (C), 0.5 h (D) and 24 h (E) post-injection of nanoparticles. Permission obtained from Ref. [72]. Copyright (2014) by Ivyspring.



= Porphyrin, HPPH or Texaphyrin

Fig. 6. The structure of a sample Mn-porphyrin-phospholipid and assembled Mn-porphyrin liposome such as Mn-porphyrin-liposomes [74], Mn-nanotexaphyrin [75], Mn-HPPH liposome and Mn-N-HPPH liposomes [76]. The Mn-porphyrin is conjugated to the side chain of a lysophospholipid and the obtained Mn-porphyrin-lipid self-assembles in a bilayer structure.

Another approach involved covalently conjugating Mnporphyrins on the surface of doxorubicin (DOX)-loaded PLA nanoparticles (MnP-Dox NPs) [71]. MnP-Dox NPs were internalized by HeLa cells and suppressed cancer cell growth due to faster drug release in an acidic environment than in a neutral pH condition. As an MRI contrast agent, MnP-Dox NPs (r_1 value of 27.8 mM⁻¹ s⁻¹) exhibited enhanced relaxivity and high performance in T1-weighted MRI both in vitro and in vivo. Gradual accumulation of MnP-Dox NPs resulted in MR signal enhancement in tumors 24 h after intravenous injection of nanoparticles (100μ L, 8 mg/mL). Photodynamic therapy was performed by encapsulating the free porphyrin as the photosensitizer, for MRI-guided PDT cancer theranostic nanoparticles (TPD NPs). Taking advantage of the EPR effect, TPD NPS passively accumulated in the tumor site. The PDT and MRI capabilities of TPD NPs were optimized with loading 31% freebase porphyrin and 19% Mn-porphyrin. In mice bearing HT-29 human colon tumors, after intravenous administration, the Mn-porphyrin led to enhanced MRI signal and clear T1-weighted MR images, theoretically allowing precise delivery of the laser light. After laser treatment, compared to the control groups, tumor growth was fully inhibited [50].

PLA-coated Au nanoshells were developed that were modified by Mn-porphyrin and encapsulated doxorubicin for lighttriggered drug release due to NIR light absorption by the Au nanoshell (Fig. 5A) [72]. T1-weighted images of phantoms containing aqueous dispersions of DOX@PLA@Au-PEG-MnP NPs showed MRI contrast (Fig. 5B). The signal at the tumor enhanced over time and clear and bright images of tumor structure were observed after 0.5 h and 24 h post-injection (Fig. 5C–E). This multifunctional theranostic agent combining photothermal therapy (Au nanoshell), chemotherapy (DOX) and MRI (Mn-porphyrin) could offer a synergistically improved therapeutic treatment to cancer.

Fullerene derivatives have been combined with Mn-porphyrins [73]. By conjugating 5-(4-aminophenyl)-10,15,20-tris(4-sulfonato



Fig. 7. (A) In vivo MRI imaging of tumor (top) and lymph node (bottom) in mice administrated with Mn-nanotexaphyrin (8 mg mL⁻¹, 1.5 mL). Molecular dynamics simulations of HPPH-lipid (B) and N-HPPH-lipid (C) bilayer. Water molecules are shown as red spheres and lipids as gray wires. (D) Optical absorption and inset photo of hydrated lipid film of different formulations. N-HPPH-lipid, but not the HPPH-lipid formed a dark solution without aggregation after water addition and shaking. Permission obtained from Refs. [75] and [76]. Copyright by Wiley.

phenyl)porphyrin (APTSPP) to [6,6]-phenyl-C₆₁-butyric acid (PC₆₁-BA), the obtained PC₆₁BA-APTSPP-Mn displayed a relaxivity of 19.2 mM⁻¹ s⁻¹, a higher value than Mn-APTSPP (11.2 mM⁻¹ s⁻¹) and the clinically used MRI reagent Gd-DTPA (4.1 mM⁻¹ s⁻¹) at 0.5T. The influence of fullerene could be explained by the charge density variation of Mn(III) and steric decompression caused by PC₆₁BA, rather than the rotational correlation time.

Mn-porphyrin-phospholipid has been developed as a multifunctional building block (Fig. 6). MacDonald et al. developed porphysomes using Mn-porphyrin-phospholipid as both an MRI contrast agent and a photothermal sensitizer [74]. The Mnporphyrin porphysome was composed of 95% Mn-porphyrin lipid and 5% DSPE-PEG 2000. MR relaxivity was evaluated in both intact and disrupted conditions. In the presence of detergent, the liposome structure was disrupted and increased relaxivity was observed. Since insertion of Mn quenched the generation of singlet oxygen, the Mn-porphyrin liposome exhibited resistance to bleaching and enhancement in photothermal activity. No loss of photoacoustic signal was observed in Mn-porphyrin liposome while the freebase porphyrin liposome decreased 4 folds. The enhancement in photostability ensured good performance of Mnporphyrin liposome in repeated photothermal treatments without loss in heat production.

Based on a similar idea, Keca et al. reported Mn-texaphyrin phospholipid for MRI. Texaphyrin, a larger pyrrole-based macrocycle, offers pentadentate coordination for metal chelation with one more coordinator compared to the 4-coordination model in porphyrins [75]. The additional coordination could result in improved chelation stability in some cases. Enhanced visualization of lymphatic drainage from the tumor site to adjacent lymph nodes was detected after rabbits were injected with Mn-nanotexaphyrin (8 mg/ml, 1.5 mL) (Fig. 7A).

In Mn-porphyrin-phospholipid liposomes, increased relaxivity is observed when the intact bilayer is disrupted by detergent [74]. This suggests that increased water access within the bilayer could enhance MRI contrast performance. 2-[1-Hexyloxyethyl]-2devinylpyropheophorbide-a (HPPH) is a porphyrin derivate that has been used for photodynamic therapy [77]. Liposomes formed from HPPH-lipid were demonstrated as chemophototherapy agents with laser-trigger drug release [78]. Shao et al. reported the synthesis of an amine modified N-HPPH-lipid with the terminal of the HPPH side chain modified by the amine group [76]. Due to hydrogen bonding between the amine group and water molecules, water content in the hydrophobic bilayer was enhanced. This was shown with molecular dynamic simulation (Fig. 7B and C), X-ray diffraction and electron spin resonance analysis. The modified N-HPPH-lipid film could be solubilized rapidly with water but the HPHH-lipid film barely dissolved (Fig. 7D). In intact liposomes, this amine modification resulted in 150% higher T1 relaxivity due to the higher water content in the bilayer. When the structures were disrupted by detergent, the Mn-HPPHliposome and Mn-N-HPPH liposome exhibited almost equal T1 relaxivity. Increased MR signal in blood and liver was observed following intravenous injection and no acute toxicity was observed.

Mn-N-HPPH-lipid and Mn-texaphyrin-phospholipid liposomes are two examples demonstrating the potential application of Mnporphyrin-phospholipid liposome used in vivo. In addition, considering porphyrin liposomes have been demonstrated as a carrier of water soluble molecules and chemophototherapeutic agents [79– 84], Mn-porphyrin liposomes hold potential to be an inherently multifunctional theranostic agent with MRI, photoacoustic, chemotherapy, photothermal therapy and photodynamic therapy properties.

Although Gd-porphyrin chelation stability may not be highly robust, a series of Gd-porphyrin molecules was synthesized as T1-weighted MRI enhance contrast agents. Jahanbin et al. developed an MRI contrast agent by conjugating gadolinium *meso*tetrakis(4-pyridyl)porphyrin [Gd(TPyP)] to chitosan [85]. The Gd (TPyP) was passively absorbed into optimized chitosan nanoparticles with a narrow size distribution of 35–65 nm. No evident distortion was observed during the encapsulation process and the loading capacity Gd(TPyP) was 87%. MRI experiments showed that Gd(TPyP) chitosan nanoparticles had T1 relaxivity of 38.35 mM⁻¹ s⁻¹, 12-fold higher than the conventional Gd-based MR contrast agents such as Gd-DOTA (~4 mM⁻¹ s⁻¹ at 3 T).

Gong et al. reported a multifunctional polymeric micelle system containing a NIR dye, IR825 and chlorin e6 (Ce6), a photosensitizer which additionally served as the Gd³⁺ chelator (Fig. 8A) [86]. This nanoparticle displayed 7 times higher r_1 value than Magnevist, a clinical Gd-based T1-weighted contrast agent (Fig. 8B). In animal experiments, triple-modal fluorescence, MR and photoacoustic imaging demonstrated efficient accumulation occurred in the tumor site via the EPR effect (Fig. 8C). Inhibition of the tumor growth was achieved with the combination of photothermal and photodynamic therapy. These properties demonstrate the capability of porphyrin nanoparticles for multimodal imaging and image guided treatments [87,88].



Fig. 8. Multifunctional polymeric nanomicelles. (A) The structure of (i) DTPA-Gd, (ii) Ce6-Gd and (iii) IR825@18PMH-PEG-Ce6-Gd. (B) The T1-weighted MR images of three different contrasts at different Gd concentration. (C) In vivo MR imaging of 4T1 tumor-bearing mice administrated IR825@C18PMH-PEG-Ce6-Gd. Dashed circle highlighted the tumor site and the arrows pointed out the heart area. Permission obtained from Ref. [86]. Copyright (2014) by Wiley.



Fig. 9. Folate-receptor-targeted liposomal Gd-texaphyrin conjugated doxorubicin. The cleavage of the bond between Gd-texaphyrin and doxorubicin resulted in restoring the fluorescence of doxorubicin. Permission obtained from Ref. [94]. Copyright (2016) by American Chemical Society.

The weaker chelation stability of Gd in porphyrins has likely limited their use as chelators for MR agents. Liang et al. developed a facile one-step aqueous dispersion polymerization to fabricate polypyrrole nanoparticles from a mixture of pyrrole and pyrrole-1-propanoic acid [89]. Gd was subsequently attached using a DOTA chelator with a polyethylene glycol linker. The obtained PEGylated



Fig. 10. Preparation and structure of different T2-weighted metalloporphyrin nanoparticles. (A) Layer-by layer self-assembled fabrication of SPIONs nanocapsule. (B) The structure of SPION grafted by ZnPC. C) Schematic for the preparation of γ -Fe₂O₃@meso-SiO₂-ZnPC. Permission obtained from Refs. [95,97,98]. Copyright by American Chemical Society, Royal Society of Chemistry.

poly-pyrrole nanoparticles conjugating gadolinium chelates (Gd-PEG-PPY NPs) displayed a high T1 relaxivity coefficient of 10.6 mM⁻¹ s⁻¹, more than twice as high as Gd-DOTA at 3T magnetic field. Clear MR images of tumors were observed in mice bearing U87-MG tumors after intravenous administration of Gd-PEG-PPY NPs (100 μ L, 5 mg/ml).

Due to improved coordination, Gd(III)-texaphyrin compounds, developed by the research group of Sessler, are more stable in vivo than the corresponding Gd(III)-porphyrin analogs [90–92]. Polymer micelles encapsulating Gd-texaphyrin as an MRI contrast agent have been described [93]. Multiple copies of specific ligands for the melanocortin 1 receptor (MC1R), a cell-surface marker for melanoma, were stabilized through the Fe(III) cross-linking. These ligand-Gd-texaphyrin micelles demonstrated effective targeting to the MC1R-expressing xenograft tumors based on MR images

Another Gd-porphyrin theranostic nanoparticle was reported by Lee et al. [94]. Through a disulfide bond, Dox was conjugated with Gd-texaphyrin and resulted in Dox fluorescence quenching. Gd-texaphyrin offered MRI guidance for tracking the compound. In the presence of glutathione, the bonds were cleaved and the recovery of fluorescence at 592 nm was observed as the signal of release of free DOX. The Gd-texaphyrin conjugated Dox could be encapsulated into folate-receptor-targeted liposomes (Fig. 9). Liposomal Gd-texaphyrin showed specific uptake and cleavage to release DOX, which enhanced antiproliferative effects in cancer cells overexpressing the folate-receptor. Reduction of tumor burden was observed in two mouse tumor models (metastatic liver cancer orthotropic model and a subcutaneous KB cell xenograft model). This theranostic nanoparticle also presented enhanced T1-weighted MR imaging in vivo for detection metastatic cancer progression at the early stage.

Iron oxide compounds are often used as superparamagnetic nanoparticles (SPIONs). This type of contrast agent shortens the T2 relaxation time for T2-weighted MRI. Zn-porphyrin modified Iron oxide nanoparticles have been developed as multifunctional theranostic agents. Yoon et al. reported a layer-by layer selfassembled polymeric nanocapsule with a SPION core and a dendrimeric Zn-porphyrin shell (Fig. 10A) [95]. PEGylation provided the nanocapsule with water-solubility and the NCs displayed adequate magnetic character (>20 emu/g) for MRI applications with a T2 relaxivity (r_2) value of 93.5 mM⁻¹ s⁻¹. In another approach, Znporphyrins were used with dextran SPIONs [96]. Zn-porphyrin was covalently conjugated with the dextran-based paramagnetic nanoparticles by "click" reaction. Zn-porphyrin was used instead of the freebase porphyrin since the copper used during the "click" reaction would chelate the freebase porphyrin and result in quenched porphyrin fluorescence and singlet oxygen generation. The grafting of cationic Zn-porphyrin resulted in an increased r_2 value around 245 mM⁻¹ s⁻¹ and a high r_2/r_1 relaxivity ratio up to 27 indicating this Zn-porphyrin modified magnetic dextran nanoparticle was an efficient T2 contrast agent. This is a unique example in which a metal porphyrin was selected to prevent the chelation of another metal (copper) during synthetic reaction in order to preserve desirable fluorescence and singlet oxygen generation properties.

Phthalocyanines can form coordination complexes with zinc (ZnPC). Boudon reported a SPIO-phthalocyanine nanoparticle as a magneto-optical agent (Fig. 10B) [97]. By consecutively coating each layer, a high yield of up to 30% ZnPC grafting to the SPIO surface was achieved due to the low steric hindrance of the neighboring ZnPC and short PEG chains. This SPIO-ZnPC nanoparticle was demonstrated as a T2 MRI contrast agent with an r_1 value of $3 \text{ mM}^{-1} \text{ s}^{-1}$ and an r_2 value of $73 \text{ mM}^{-1} \text{ s}^{-1}$ ($r_1/r_2 = 24$). Xuan et al. reported the design of highly magnetized silica-coated porous microspheres with porous γ -Fe₂O₃ core in which the size of magnetic core and the shell thickness could be controlled and optimized by tuning the synthetic parameters (Fig. 10C) [98]. Hydrophobic ZnPC was encapsulated in the microsphere and this nanoparticle displayed an r_2 value of 76.5 mM⁻¹ s⁻¹.

3.2. Positron emission tomography (PET)

Single-photon emission computerized tomography (SPECT) and positron emission tomography (PET) are commonly used clinically for non-invasive, imaging diagnosis of human diseases [99]. Although both have advantages and disadvantages, compared to SPECT, PET has greater sensitivity and resolution [100]. In general, porphyrins have been widely explored as radionuclide chelators [101]. Although there have been some recent examples of using porphyrins for chelation and imaging of SPECT tracers such as



Fig. 11. 64 Cu-porphysomes as a PET agent. (A) Schematic diagram of the multimodal properties of 64 Cu-porphysomes as a result of directly radiolabeling a fraction of the porphyrin-lipid bilayer of preformed photonic porphysomes creating intrinsic multimodal nanoparticles. 64 Cu-porphysome selectivity in orthotopic prostate tumor models. Representative MicroPET/CT images of (i) axial, (ii) coronal, and (iii) sagittal single slices through (B) orthotopic PC3 tumor (n = 8), (C) orthotopic 22RV1 tumor (n = 3), and (D) healthy male mice (n = 3) at 24 h after intravenous injection of 500 µL Ci 64 Cu-porphysomes: PET image integration time 40 min. White arrows depict prostate tumor; blue arrows depict bladder. Permission obtained from Ref. [112]. Copyright (2013) by American Chemical Society.



Fig. 12. ⁶⁴Cu-PoP coated UCNPs as a multifunctional imaging agent. (A) Schematic diagram of the PoP-UCNP structure. Core-shell UCNPs were transferred to the aqueous phase by lipid coating with PEG-lipid and PoP. Radioactive ⁶⁴Cu can seamlessly chelate inside the macrocycle of the PoP. (B) Accumulation of PoP-UCNPs in the first draining lymph node is indicated with yellow arrows in full anatomy PET (left), merged PET/CT (right). Permission obtained from Ref. [113]. Copyright (2015) by Wiley.

¹¹¹In and ^{99m}Tc [102,103], we will focus on nanoparticulate PET approaches.

Porphyrins and phthalocyanines are promising PET agents as they are also NIR fluorophores, are biologically compatible, metal complexes are thermodynamically and kinetically stable, and they usually exhibit some specificity for tumors, with or without the presence of a coordinated metal in the central core [104,37,105]. Cu-phthalocyanine was described as a ⁶⁴Cu chelator that accumulated in rodent brain tumors as early as 1951 [106]. The physical properties and availability of ⁶⁴Cu make it a useful nuclide for PET imaging: $t_{1/2}$ = 12.7 h, β +: 17.4%, $E_{\beta+max}$ = 656 keV [107]. The in vivo pharmacokinetics and biodistribution of porphyrins are generally not altered by chelation with ⁶⁴Cu [107–109].

The Zheng group investigated incorporating ⁶⁴Cu into a porphyrin-peptide-folate (PPF) probe as a folate receptor (FR) targeted fluorescent/PDT agent [110]. ⁶⁴Cu-PPF uptake in FRpositive tumors was apparent with small animal PET with a high tumor-to-muscle ratio of 8.9 observed after 24 h. Competitive blocking studies confirmed the specificity of the FR-mediated tracer uptake in the tumor. This concept was advanced from peptide to nanoparticle, when it was discovered that organic porphysome nanoparticles could function as seamless ⁶⁴Cu radiotracers [111]. Incubation of ⁶⁴Cu with pre-formed nanoparticles in appropriate conditions resulted in a fast (30 min), one-pot, high yielding (>95%) procedure producing stable radiolabeled nanoparticle (Fig. 11A) The intrinsic ability of the porphysomes to directly



Fig. 13. Self-assembled multifunctional nanoporphyrin. (A) Schematic illustration of a multifunctional NP self-assembled by a representative porphyrin-telodendrimer, PEG5k-Por4-CA4, composed of four pyropheophorbide-a molecules and four cholic acids attached to the terminal end of a linear PEG chain. (B) PET image of nude mice bearing SKOV3 ovarian cancer xenografts at 4, 8, 16, 24 and 48 h post injection of ⁶⁴Cu-labeled NPs (150–200 ml, ⁶⁴Cu dose: 0.6–0.8 mCi). The white arrow points to the tumor site. (C) PET-MR images of tumor slices of nude mice bearing A549 lung cancer xenograft at 4 or 24 h post injection of dual-labeled NPs. White arrow points to the necrotic area in the center of the tumor. Permission obtained from Ref. [117]. Copyright (2014) by Springer Nature.

chelate ⁶⁴Cu allows them to be accurately and noninvasively tracked in vivo. Only a fraction of the porphyrin-lipid bilayer is directly labeled with copper, thereby preserving NIR fluorescence properties. This approach was used for tracking and real-time delineation of orthotopic prostate tumors and micrometastases [112]. This successful application of ⁶⁴Cu-porphysomes in clinically relevant orthotopic and metastatic cancer models is promising for translation. Clear multimodal delineation (using both PET and fluorescence) of orthotopic tumors on both the macro- and the microscopic scales was observed, as was sensitive detection of small metastases (<2 mm) (Fig. 11B, C and D).

Porphyrin-phospholipid can also be used to coat existing nanoparticles and confer seamless PET labeling and contrast. This strategy was adopted using porphyrin-phospholipid to coat UCNPs. This simple approach yielded nanoparticles that could be used in 6 different imaging modalities, including Cerenkov luminescence and PET imaging, which were enabled by ⁶⁴Cu labeling (Fig. 12A) and lymphatics imaging was demonstrated (Fig. 12B) [113]. Expanding the concept of seamless ⁶⁴Cu labeling for multimodal imaging, a porphyrin polymeric mesh was developed using tetracarboxylic porphyrins and PEG diamines as polymer monomers [114]. Following intravenous administration the porphyrin mesh was rapidly cleared via renal excretion in healthy mice but not mice suffering from rhabdomyolysis acute renal failure. Renal clearance was monitored by fluorescence analysis and seamless whole body ⁶⁴Cu PET imaging. In another example, surfactantstripped micelles were developed from pheophytin or naphthalocyanines that results in micelles with very high cargo-to-excipient ratios [115,116]. These micelles can be seamlessly labeled with ⁶⁴Cu for whole body gut imaging.

Li et al. developed a versatile 'all-in-one' porphyrin-based organic nanoconstruct termed nanoporphyrin that was selfassembled with a single organic building block, a porphyrin/cholic acid (CA) hybrid polymer (Fig. 13A) [117]. PET imaging following seamless ⁶⁴Cu labeling showed the nanoporphyrin started to accumulate at tumor sites 4 h after injection, and reached maximum level at 16 h. After 24 h, the radiolabel was found primarily at the implanted tumors, with low background in the rest of the body (Fig. 13B). The versatility of the approach was extended by developing dual-modality nanoprobes by synergistically combining PET and MRI to provide accurate diagnoses. Both ⁶⁴Cu(II) and Gd (III) could be efficiently incorporated into nanoporphyrin for both MRI contrast and PET tumor imaging [117]. Heterogeneous tumor uptake distribution was revealed using PET-MRI (Fig. 13C) [117].

Feng and colleagues used a liposome approach with a sequential activation pattern by encapsulating a hydrophobic photosensitizer chlorin e6 (Ce6) into the bilayers and AQ4N into the aqueous cavity of PEGylated liposomes [118]. The AQ4N-Ce6-liposome demonstrated hypoxia-dependent cytotoxicity and photodynamic cell killing ability. In addition to its inherent contrast with fluorescence and photoacoustic imaging, seamless ⁶⁴Cu chelation conferred capabilities as a PET imaging probe. After intravenous injection of AQ4N-⁶⁴Cu-Ce6-liposomes into BALB/c mice bearing 4T1 tumors (~10 MBq per mouse), the liposomes accumulated in tumors. Ex vivo distribution was carried out by recording the radioactivity extracted tissues. Tumor accumulation was measured



Fig. 14. Porphyrin-lipid coated gold nanoparticles as SERS agents. (A) The structure of MnPL AuNPs. The Mn-porphyrin lipid was served as both the SERS dye and the biocompatible surface coating. (B) The microscopy images of A549 lung cancer cells showing MnPL AuNP used for cellular imaging. Permission obtained from Ref. [125]. Copyright (2012) by American Chemical Society.



Fig. 15. Zn-MeO-porphyrin lipid nanovesicles for PA contrast agent. (A) Photographs of Zn-MeO-chlorin acid (20%) and Zn-MeO-chlorin lipid (20%) after storage at room temperature for 10 days. Precipitation was observed in the Zn-MeO-chlorin acid sample after 10 days of storage. (B) UV-vis absorption and CD spectra for 20% Zn-MeO-chlorin lipid. (C) PA image of hamster cheek pouch tumor pre-injection and 5 min post-injection of the Zn-MeO-chlorin lipid nanovesicle. (D) Quantitative analysis of the PA signal in the tumor site pre-injection and 5 min post-injection of the Zn-MeO-chlorin lipid nanovesicle. (D) Quantitative analysis of the PA signal in the tumor site pre-injection and 5 min post-injection of the Zn-MeO-chlorin lipid nanovesicle. (D) Quantitative analysis of the PA signal in the tumor site pre-injection and 5 min post-injection of the Zn-MeO-chlorin lipid nanovesicle. (D) Quantitative analysis of the PA signal in the tumor site pre-injection and 5 min post-injection of the Zn-MeO-chlorin lipid nanovesicle. (D) Quantitative analysis of the PA signal in the tumor site pre-injection and 5 min post-injection of the Zn-MeO-chlorin lipid nanovesicle. (D) Quantitative analysis of the PA signal in the tumor site pre-injection and 5 min post-injection of the Zn-MeO-chlorin lipid nanovesicle. Permission obtained from Ref. [129]. Copyright (2016) by American Chemical Society.

to be 4.7% ID g⁻¹, comparable to the in vivo PET imaging analysis. This approach shows that not only PET imaging can non-invasively assess pharmacokinetic and time-dependent biodistribution, but the use of porphyrin nanoparticles has the advantage of having the option to use ⁶⁴Cu to conveniently gain critical information about pharmacological behavior.

3.3. Optical imaging

3.3.1. Surface enhanced Raman scattering (SERS)

Surface enhanced Raman scattering (SERS) based on gold nanoparticles (AuNPs) is a promising technique for bioanalysis and diagnosis [119–122]. By analyzing Raman signatures, highly multiplexed analysis of nanoparticles is possible. Porphyrins are potential SERS agents [123]. SERS analysis can be used to understand how various metalloporphyrins (e.g. Fe, Ni, Cu) interact on the surface of AuNPs [121]. 5,10,15,20-Tetra(4-pyridyl)-21H,23H-

porphine metallocomplexes (M-TPyP, M = Cu, Fe. Ni) were linked onto AuNP surfaces in various proportions to form well-ordered monolayers for analysis.

Phospholipid coating can enhance AuNP stability and biocompatibility for biological applications [124]. However, the strong fluorescence of freebase porphyrin can interfere with SERS signal detection. Tam et al. reported that fluorescently quenched Mn-porphyrin phospholipid could be used as both a stabilizing, biocompatible surface coating agent and Raman dye to encapsulate the AuNPs for SERS imaging (Fig. 14A) [125]. Mn-porphyrin lipid coated AuNPs showed clear uptake in A549 lung cancer cells based on Raman micrographs (Fig. 14B). This is the first use of porphyrins as a SERS reporter molecule in contrast enhanced imaging and offers convenient control of the Raman dye on the AuNPs.

Similar to Mn-porphyrin phospholipid, palladium-porphyrin phospholipid (PdPL) was also reported for SERS imaging, when coupled with plasmonic nanoparticles [126]. The obtained



Fig. 16. TAA-UCNP co-loaded with PdOEP and DPA. Schematic illustration of TAA-UCNP, the chemical structure of PdOEP (sensitizer) and DPA (annihilator). The chelation of palladium (Pd) enhanced the phosphorescence of porphyrin molecules and thus it has the potential to be used as a triplet photosensitizer for upconversion. Permission obtained from Ref. [134]. Copyright (2012) by American Chemical Society.



Fig. 17. TTA-UCNP composed of BSA-dextran stabilized oil droplets, co-loaded with PtTPBP and BDP dyes. (A) The schematic illustration of TTA-UCNP composed of PtPBP (sensitizer) and BDP dyes (annihilator). The BSA-dextran stabilized oil droplets system enhanced the solubility of encapsulated agents. (B) In vivo (top) and in situ (bottom) lymph node upconversion luminescence imaging of living mice at 30min after intradermal administration with the TTA-UCNP through paws (BDP-G for the forepaw and BDP-Y for the hindpaw). Permission obtained from Ref. [135]. Copyright (2013) by American Chemical Society.

PdPL-NPs can serve both as SERS reporters and PDT photosensitizers at the same wavelength (638 nm), allowing the potential realtime monitoring of photosensitizers in vivo through the SERS signal. Compared with fluorescence tracking of photosensitizer, SERS eliminates reliance on fluorescence so that the absorbed light energy can be fully directed toward enhanced PDT efficacy.

3.3.2. Photoacoustic contrast

Porphyrins and its derivatives have been evaluated and successfully utilized as contrast agents in photoacoustic (PA) imaging [56,127,128]. Recently, Ng et al. reported a novel design of metalloporphyrin for the photoacoustic application [129]. The Znporphyrin was modified with a formyl side chain and conjugated to a hydroxyl lysolipid. The obtained Zn-MeO-porphyrin lipid self-assembled into a bilayer structure, improving colloidal stability (Fig. 15A). The advantage of using Zn-porphyrin instead of freebase-porphyrin was that within the lipid bilayer structure, the Zn formed the coordination with MeO group resulting in a 72 nm bathochromic shift in the Q_y band. This shift was not observed in its monomeric state, or in presence of detergent. In addition, circular dichroism demonstrated the presence of active chiral Znporphyrin structure within the bilayer (Fig. 15B). PA imaging of 20% Zn-MeO-chlorin-lipid nanovesicles was detectable in the tumor-bearing mice after intravenous administration (Fig. 15C). An obvious increase in PA signal was observed 5 min after the administration of Zn-MeO-chlorin-lipid nanovesicles (Fig. 15D).

3.3.3. Upconversion sensitizer

Chelation of heavy metal atoms into porphyrins, such as palladium (Pd) or platinum (Pt), enhances the triplet state conversion and phosphorescence. For example, the Pd-TPP has a quantum yield of phosphorescence of $\Phi P = 0.17$ whereas the freebase TPP has a quantum yield $\Phi P = 4 \times 10^{-5}$. Upconversion luminescence is an anti-Stokes energy process and offers distinct advantages in bio-imaging, including elimination of background fluorescence from both endogenous chromophores and conventional fluorescent probes [130–132]. One of the preparation strategies of the UCNPs is based on triplet-triplet annihilation (TTA) upconversion. Due to the independent selection of the sensitizer and annihilator, compared with UCNPs prepared by rare-earth-based materials codoped with Yb³⁺ and Er³⁺, TTA upconversion nanoparticles (TTA-UCNP) could be designed with adjustable and tunable excitation and emission. A benzene solution of Pt(II) tetraphenyltetrabenzo porphyrin (sensitizer) and BODIPY dye showed a TTA-based Φ UCL of 15% which is higher than many Yb^{3+} based UCNP [133].

Liu et al. reported successful fabrication of water-soluble TTA-UCNP with Φ UCL of 4.5% in aqueous solution by coloading a photosensitizer (Pd-octaethylporphyrin) and annihilator (9,10-diphenylanthracene) into silica nanoparticles (Fig. 16) [134]. This TTA-UCNP showed good photostability and low cytotoxicity. In vitro confocal imaging in live Hela cells and in vivo lymphatic imaging showed that TTA-UNCP could be applied for upconversion luminescence imaging with high signal-to-noise ratios.

The same group reported another TTA-UCNP using Pt(II)-tetra phenyl-tetrabenzoporphyrin (PtTPBP) and BODIPY dyes (BDP-Green and BDP-Yellow) (Fig. 17A) [135]. The TTA-UCNP was prepared by loading both sensitizer and annihilator into BSA-dextran stabilized oil droplets, instead of the previous used SiO₂-coating nanosystems which gave a weak UCL emission (Φ UCL < 0.1%) due to the aggregation-induced fluorescence quenching of annihilators. The BSA-dextran stabilized oil droplets system achieved better upconversion efficacy (Φ UCL for BDP-Green UCNP = 1.7% and Φ UCL for BDP-Yellow UCNP = 4.8%) by maintaining high translational mobility of chromophores to avoid the aggregation-induced luminescence quenching. The obtained the TTA-UCNP could be used as a potent probe for in vivo lymph node imaging of mice (Fig. 17B).

3.4. Photodynamic therapy (PDT) agents

Photodynamic therapy (PDT) is a photoablative technique that has been used for the treatment of various solid tumors. Upon excitation with a specific wavelength of laser irradiation, an activated photosensitizer (PS) can interact with molecular oxygen to produce reactive oxygen species (ROS) including singlet oxygen ($^{1}O_{2}$), hydroxyl radicals (.OH) and superoxide (O_{2}^{-}) ions resulting in cell death and tumor destruction [136–138].

Zn-porphyrins have been used extensively in the PDT. As a suitable NIR emitting fluorophores, most Zn-porphyrin or Zn-phthalocyanine photosensitizers have an excitation band in the 650–800 nm range, a fluorescence quantum yield $\Phi F = 0.04-0.3$, and a molar extinction coefficient around $\varepsilon = 10^5 \text{ M}^{-1} \text{ cm}^{-1}$ [139–143]. Additionally, the stable chelation between Zn and porphyrin molecules protects the fluorescence from being quenched due to the unexpected chelation of other metals, like the Cu.

PEGylated SPIONs containing Zn-porphyrin generated intracellular ROS after the light irradiation. And using the HeLa cells as a model cell line, cellular phototoxicity experiments showed decreasing cell viability as a function of irradiation time and the numbers of Zn-porphyrin coated layers [95]. The PDT effect of serial Zn-porphyrin magnetic dextran nanoparticles (PS/MNP) was evaluated against the HaCaT cell line. The neutral and cationic PS/MNPs, but not the ionic ones exhibited high cell-uptake and cytotoxicity after irradiation. The confocal microscopy presented a relative colocalization of Zn-porphyrin and mitochondria indicating the PS/MNPs leaded to the tumor cell death by intrinsic apoptotic pathway and subsequent elimination by phagocytosis [96].

Hydrophobic zinc(II) phthalocyanine (ZnPC) was encapsulated into magnetic microspheres composed of porous γ -Fe₂O₃core and porous SiO₂ shell. Due to the large BET surface area 222.3 m²/g, the biocompatible microsphere with 170 nm size showed the loading capacity of ZnPC up to 53 mg/g. The ZnPC microspheres were demonstrated to be internalized by T29 human colorectal carcinoma cells and showed 80% cytotoxicity with the light irradiation [98].

A common problem and dose-limiting factor associated with PDT is undesired acute phototoxicity during treatment or sunlight phototoxicity following treatment. Carter et al. reported a detailed study on the therapeutic activity of metalloporphyrin-phospholipid liposomes based on HPPH-phospholipid conjugates. Cu(II) or Zn(II) was chelated into the HPPH-phospholipid [144]. Compared with the freebase HPPH liposome, Cu chelation quenched more than 90% fluorescence and significantly reduced the generation of singlet oxygen, thereby attenuating all PDT efficacy. The Zn-HPPH liposome retained fluorescence and generation of singlet oxygen allowing it to permeabilize tumor vasculature and enhance delivery of mitoxantrone to the target tumor. Uniquely, the Zn-HPPH-lipid liposome exhibited strong self-bleaching effects under laser irradiation, thereby reducing phototoxicity. Photobleaching was observed in mice treated with laser irradiation at 24h postinjection with Zn-HPPH-lipid liposome compared to the freebase ones (Fig. 18). Lethal phototoxicity occurred with freebase, but not Zn HPPH liposome phototreatment. Zn-HPPH-lipid was used as an efficient antitumor drug carrier in vivo with light-triggered release with eliminated phototoxicity.



Fig. 18. In vivo imaging of HPPH-lipid fluorescence pre- and post-laser exposure. Mice were administrated intravenously equal doses (11 mg/kg) three types of HPPH-liposomes and treated with a 665 nm laser at a fluence rate of 200 mW/cm² for 12.5 min (150 J/cm²) 24 h post-injection. Cu-PoP did not show fluorescence and Zn-PoP showed a rapid self-bleaching. Permission obtained from Ref. [144]. Copyright (2016) by American Chemical Society.



Fig. 19. pH sensitive metalloporphyrin NPs loaded with Dox. (A) Illustration of the dual pH sensitive mesoporous silica nanoparticle (MSN). ZnPor-CA-PEG formed the metallosupramolecular-coordination complex and attached on the MSN surface via the chelation between ZnPor and histidine. The bond between CA and ZnPor was cleaved in the extracellular environment with pH ~6.8, resulting in a positively charged nanoparticle and facile cellular internalization. In intracellular acidic microenvironments (pH ~5.3), the chelation between histidine and ZnPor was broken and the encapsulated drug released. (B) The structure of Dox loaded ZnPor supramolecular nanogel. Permission obtained from Refs. [51,146]. Copyright by Elsevier and Royal Society of Chemistry.

In another example, ZnPC was encapsulated into poly (D,L laticco-glycolic acid) (PLGA) PLGA nanoparticles with 70% efficiency using a solvent emulsion and evaporation method [145]. 15% of the ZnPC rapidly released in the first 3 days and another 25% released more slowly during a period of 25 days. In vitro, up to 60% cell death was observed in P388-D1 cells treated with the combination of ZnPC-PLGA nanoparticle and light irradiation.

Some chelated metals in porphyrins can form metallosupramolecular coordination complex with the other molecules, like histidine. Yao et al. designed a dual pH sensitive MSNP in which the PEGylated tetraphenylporphyrin zinc (ZnPor-CA-PEG) was used as the "gate keeper" to control the release of loaded drug [146]. The ZnPor-CA-PEG formed a metallosupramolecular-coordi nation complex, preventing the loaded drug from leaking out, with the histidine grafting on the surface of silica nanoparticles. In extracellular environments where the pH was ~6.8, the binding between acid sensitive *cis*-aconitic anhydride (CA) and ZnPor was cleaved resulting in cellular internalization of the nanoparticles. Cellular internalization of the MSNP-ZnPor-CA-PEG was demonstrated by confocal laser scanning microscopy. The metallosupra molecular-coordination complex was broken down in intracellular acidic microenvironments (pH \sim 5.3) to release drugs like DOX. ZnPor and the released Dox offered the combination the chemotherapy and PDT (Fig. 19A). In vitro, in Hela and MCF-7 cell lines, the treatment of Dox-loaded MSNP-Por-CA-PEG with irradiation displayed the highest cytotoxicity compared with control groups. The combination of chemotherapy and PDT has emerged as a promising treatment modality for solid tumors [147].

Based on similar principles, using metallosupramolecular-coor dination complexation between ZnPor and histidine, a novel metallosupramolecular nanogel (SNG) loaded with Dox was designed by the same research group (Fig. 19B). The Dox-loaded ZnPor-SNG responded to the intracellular acidic environment to release the ZnPor and DOX. Both in vitro and in vivo experiment revealed that the Dox-loaded ZnPor SNG with irradiation was a more efficient antitumor treatment than the single chemotherapy of free doxorubicin (DOX) or photodynamic therapy of Zn-Por in SNG [51].

Like Zn, the chelation of aluminum (Al) only partially quenches the fluorescence and singlet oxygen, allowing applications for PDT. Many reported Al photosensitizers are Al-phthalocyanine based agents, including the clinically-used sulfonated photosensitizers [148]. Muehlmann reported poly(methyl vinyl ether-co-maleic



Fig. 20. Schematic illustration of preparation of FASOC-UCNP-ZnPC nanoparticles and folate-mediated binding to tumor cells. ZnPC was encapsulated into the FASCO-UNCP as the PDT agent. The UCNP absorbs 980 nm light and activates the ZnPC which has a 660 nm excitation wavelength. This nanoparticle could be uptaken specifically by tumor cells overexpressing the folate receptor. Permission obtained from Ref. [153]. Copyright (2013) by American Chemical Society.

anhydride) nanoparticles (PVM/MA NPs) loaded with aluminumphthalocyanine chloride (AlPc) [149]. The association of AlPc with PVM/MA NPs was based on solvent displacement in the presence of 1.5% Tween 20 to prevent the precipitation of AlPc. At an initial AlPc concentration of 10 μ M, association efficiency reached 30%. Due to the nanostructure, water dispersion of AlPc was enhanced resulting in strong fluorescence and better photochemical performance. In vitro PDT with 4T1, NIH/3T3 (murine) and MCF-7 (human) cancer cells demonstrated photocytotoxicity of AlPc NPs at 0.25 μ M concentration. Interestingly, in the absence of light, the cytotoxicity of AlPc at high concentrations was observed in cancerous cell lines but not MCF-10A cells which represent normal breast tissue. At a lower laser energy density (0.48 J/cm²), apoptosis was predominant via typical oxidative stress-induced apoptosis pathways. Higher laser energies density destroyed cell structures, like the cell membrane, resulting in a predominant mechanism of cell death by necrosis, which additionally induces inflammatory response that can be useful against the remaining tumor cells.

One determining factor for an effective photosensitizer is the penetration depth of the excitation light. Most porphyrin-based photosensitizers use a visible light absorption band between 600 and 700 nm. Upconversion nanoparticles (UCNPs) are an emerging nanomaterial that can absorb lower-energy, further red-shifted, NIR irradiation, which has deeper penetration depth, and convert it to higher-energy visible light for photosensitizer excitation [150]. Tetracarboxylic aluminum phthalocyanine AlC₄Pc has been used as a photosensitizer with MSNPs [151] and can be encapsulated inside the silica shell of UCNPs [152]. These UCNP@SiO₂(AlC₄-Pc) generated singlet oxygen efficiently under NIR light. Generation of singlet oxygen from UCNP@SiO₂(AlC₄Pc) occurred under 980 nm laser irradiation (500 mW cm⁻²). In vitro experiments showed NIR-induced photodynamic cytotoxicity of UCNP@SiO₂(AlC₄Pc) against murine liver cancer cells. Up to 40% cell death was observed in the group treated with UCNP@SiO2 (AlC4Pc) and 980 laser irradiation for 5 min.

Cui et al. reported ZnPc modified upconversion nanoparticles as a theranostic agent [153]. Folate-modified amphiphilic chitosan (FASOC) was coated on the surface UCNPs and enabled the encapsulation of ZnPc with high loading efficiency. In vitro confocal and NIR imaging demonstrated the enhanced specific uptake of the UCNPs in cancer cells overexpressing the folate receptor. The UCNPs, absorbing 980 nm irradiation, efficiently transferred energy to activate ZnPc. In 1 cm tissue, the UNPCs displayed a higher production of singlet oxygen under 980 nm excitation light than that under 660 nm excitation light (which directly can excite ZnPc, Fig. 20). In vivo fluorescence imaging demonstrated targeting and active accumulation of FASOC-UCNPs in Bel-7402 tumors in nude mice. When 1 cm pork tissue was placed on top of the skin over the tumor site, improved PDT was observed with 980 nm treatment compared to the 660 nm treatment. When irradiated through 1 cm tissue, tumor inhibition was 18% with 660 nm exci-



Fig. 21. A dual activatable photosensitizer. Si allows axial coordination of two different ligands for a dual activatable photosensitizer (DTT = dithiothreitol). Permission obtained from Ref. [154]. Copyright (2014) American Chemical Society.



Fig. 22. Binding between CoPoP liposomes and his-tagged polypeptides. (A) Schematic illustration of the his-tagged polypeptide binding with CoPoP. The his-tag is buried within the hydrophobic lipid bilayer. Only a single leaflet of the bilayer structure is shown. (B) Stable binding between CoPoP liposomes and a his-tagged protein was demonstrated by fluorescence imaging of a native electrophoresis gel. The arrows indicate the position of the liposomes. Only in the CoPoP sample did the positions of metalloporphyrin liposomes and protein coincide. Permission obtained from Ref. [155]. Copyright (2015) by Springer Nature.

tation, but 50% with 980 nm excitation. Thus, FASOC-UNPC-ZnPc represents a platform for targeted drug delivery and deep-tissue PDT.

3.5. Axial coordination

Si, Sn and Co chelates offer additional options to impart structure to porphyrin assemblies through axial coordination. This is illustrated in Fig. 21, in which a silicon(IV) phthalocyanine was connected with two separate axial ligands to impart photosensitizer responsiveness to two separate biological stimuli through with cleavable axial quenching ligands [154].

Axial coordination of metalloporphyrins can operate on preformed nanoparticles and can potentially avoid exposure to organic solvents and chromatography purification. Shao et al. reported stable chelate binding between polyhistidine-tagged (his-tag) proteins and cobalt-porphyrin via the metal axial coordination [155]. The Co-porphyrin was conjugated with lysophospholipid to obtain Co-porphyrin-phospholipid (Co-PoP) and further self-assembled into liposomes in the aqueous condition where the Co-porphyrin stayed in the hydrophobic layer (Fig. 22A). After aqueous incubation with Co-PoP liposome, his-tagged polypeptides or proteins were anchored into liposome bilayer via the his tag. The attachment of protein was demonstrated by the fluorescence images of electrophoretic mobility shift assay (Fig. 22B). This binding between histidine and Co-PoP via the axial coordination showed enhanced stability both in the presence of excessive competitors (imidazole) and in biological conditions (50% serum). In addition to the kinetic inertia of Co(III), the protection provided by the liposome structure was another factor of the stable axial coordination between CoPoP and histidine since the binding occurred within the sheltered hydrophobic bilayer. Using this approach, the Co-PoP liposome was modified with his-tag RGD peptide and the obtained ligand-targeted liposomes and also used as an antigen delivery system for peptides. This approach also offers good potential for use as an antigen delivery system for proteins [156].

Fullerene has been explored as a building block for nanostructured agents due to its small size, distinct shape and unique physicochemical properties. Dyads and triads composed of fullerene complexes with coordination assemblies of metalloporphyrins have been reported for effective photoinduced charge transfer (CT) agents with long-lived charge-separated states [157–160].

Even without surface modification, fullerene can form coordination bonds with metalloporphyrins. Many different central metal porphyrins have demonstrated coordination with neutral fullerene [161–163], especially Fe-porphyrins which form the strongest bonding to neutral fullerenes among metalloporphyrins of the first-row [164]. Cobalt(II)-tetraphenylporphyrin (CoTPP) formed an axial coordination complex with ionic fullerene due to Co-C (fullerene[–]) bonds, however, other metals such as zinc, manganese or copper failed to form such stable metal–carbon bonds. A series of CoTPP-C₆₀ complexes were developed, and due to strong exchange interaction, reversible transitions from diamagnetic to paramagnetic state were observed in some compounds when dissociation occurred between CoTPP and C₆₀ as the temperature increased [165–167].

The surface of fullerene can be modified with aromatic molecules containing nitrogen atoms, such as imidazoles or pyrroles, and become the axial coordination ligand for metalloporphyrins. Konarev at el reported a pyrrolidinofullerene DP3FP and its triad complex with two Mn^{II} tetraphenylporphyrins (Mn^{II} TPP) [168]. Through microwave-assisted synthesis, DP3FP could be easily and quickly prepared with two chelating pyridyl groups. The DP3FP could be considered as the axial coordination ligands and form well-ordered complexes with two Mn^{II}TPP at the same time. X-ray single crystal diffraction showed that the lengths of axial coordination Mn–N(DP3FP) bonds for both Mn^{II} TPP was 2.2 Å. The chelation resulted in distortion of the porphyrin rings to an umbrella shape with the Mn displaced by 0.4 Å out of the porphyrin plane. Optical experiments demonstrated very weak electronic interactions between the porphyrin and pyrrolidinofullerene and absence of charge transfer in the ground state in the DP3FP Mn^{II} TPP complex (Fig. 23A).

Ince et al. reported non-covalent and covalent donor–acceptor systems based on Zn porphyrin- C_{60} fullerene derivatives [52]. Compared to covalent conjugation, axial coordination ligand showed a nearly nanosecond radical ion pair state (0.78 ns) indicating good electronic coupling between the excited state electron donor and the ground state electron acceptor. However, no electron transfer was observed in the covalent conjugation compounds, demonstrating poor electronic coupling through covalent binding. This study revealed that dyads composed of fullerene and metalloporphyrin through axial coordination can potentially form better photoactive materials.

Song et al. developed a porphyrin-fullerene dyad axial coordination reaction by combining pyridyl-modified C_{60} with equimolar tetraphenylporphyrinozinc (ZnTPPH) in hexane at room temperature (Fig. 23B) [169]. Due to the strong intramolecular electron transfer between the photoexcited ZnTPPH to its axial ligand C_{60} , the ZnTPPH-fullerene dyad showed a 71% decrease of the intensity compared to that of the 1:1 mixture of ZnTPPH with fullerene. A



Fig. 23. The structure of a metalloporphyrin-fullerene compound. (A) Structure of triad complex composed of DP3FP and two Mn^{II} TPP. Two pyridines were grafted on the surface of fullerene. The nitrogen atoms in pyridine further coordinated with Mn^{II} TPP and formed the triad complex. (B) The structure of ZnTPPH-fullerene dyad used in the photoinduced H_2 evolution. Pyridine was conjugated on the surface of C_{60} and further occupied the axial coordination position of ZnTPPH as the ligand. This Zn-TPPH-fullerene dyad was applied for photoinduced H_2 evolution. Permission obtained from Refs. [168] and [169]. Copyright by Royal Society of Chemistry and American Chemical Society.



Fig. 24. Schematic illustration of a drug formulation for oral administration of a SOD mimic (Mn-Ls/Alg). The SOD agent, Mn-porphyrin (Mn-Ls), formed the liposome with DMPC and cholesterol. The liposome was encapsulated in alginate hydrogel matrix (Alg). Permission obtained from Ref. [177]. Copyright (2015) by Royal Society of Chemistry.

five-component system consisting of an electron donor (EDTA), this ZnTPPH-fullerene dyad, an electron mediator MV^{2+} , catalyst colloidal Pt, and a proton source (HOAc), was designed to investigate photoinduced H₂ evolution. With 4 h irradiation, the turnover number of H₂ evolution using ZnTPPH-fullerene dyad could reach 73, which was much higher than that of the ZnTPPH alone (2.3). H₂ evolution was not observed in the absence of any one of these five components, or without irradiation.

3.6. Superoxide dismutase (SOD) mimicking agents

Cell death via ROS induced by metalloporphyrins with superoxide dismutase (SOD) activity has been studied. By converting intracellular O_2^- into H_2O_2 , DNA damage can be induced which induces cell death. Fe-porphyrin was demonstrated as a promising SOD mimic with significant cytotoxicity [170,171]. However, suitable carriers could benefit in vivo delivery of SOD mimetics. pHsensitive liposomes mainly composed of phosphatidylcholine (DMPC) and cationic/anionic lipid combination have been designed for this purpose. It could deliver the Fe-porphyrin into the cytosol when exposed to the acidic environments of the endosome [172– 174]. The strong electrostatic interaction between the cationic Fe-porphyrin and the ionic lipid head could remain intact in vivo. The liposome carrier with 30 nm size enhanced the cell uptake of the Fe-porphyrin compared to the free Fe-porphyrin delivery. It showed high cytotoxicity without phototoxic effect toward the Lewis lung carcinoma cell line and MKN28 cell line.

Besides Fe-porphyrin, Mn-porphyrin has been recognized as another potential SOD mimic for anticancer therapy. The Mnporphyrin modified liposome has been demonstrated as an antioxidative agent for both SOD and peroxidase (POD) [175]. Various types of phospholipids, such as 1,2-distearyl-*sn*-glycero-3phosphocholine (DSPC), 1,2-dimyristoyl-*sn*-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-*sn*-glycero-3-phosphocholine (DPPC), and 1,2-dilauroyl-*sn*-glycero-3-phosphocholine (DLPC) were used as the major lipids to form liposomes to optimize the maximum SOD and POD activity. The DMPC-based Mn-porphyrin modified liposome produced higher SOD activity, which was due to the well-dispersed ligand on the membrane in the liquid crystalline phase, and maximal POD activity which was due to cluster type of Mn-porphyrin on the membrane in the gel phase. Liposomes combined with Tween-80 and retaining Mnporphyrins could act as SOD agent that could absorb the ApoE. By taking advantage of ApoE-induced transcytosis, it could be delivered across the blood-brain barrier and the Mn-porphyrin was observed in preliminary in vivo experiment [176].

Stearate-modified Mn-porphyrin could be formulated with an alginate hydrogel carrier matrix system and formed particles around 130 nm in size (Fig. 24) [177]. This orally administered drug delivery system protected the Mn-porphyrin pass through the acidic gastrointestinal environment for intestinal delivery and resulted in antitumor effects by the O_2^- inhibitory activity of the Mn-porphyrin. However, the total Mn-porphyrin encapsulation efficiency was only 2%.

3.7. Oxygen sensing

The sensing of biological analytes is a promising topic for metalloporphyrins [178]. As demonstrated above (Fig. 21), axial ligation can impart analytical sensing functionality to metalloporphyrins. Various metals are emerging as sensors; for example, Si imparts reversible pH-responsive fluorescence [179]. However, oxygen sensing with Pd- and Pt-porphyrins is one of the most well-established sensing approaches.

Oxygen concentration and consumption within tissues and cells are critical parameters for metabolism and cell viability. The information gained from the measurement and imaging of the tissue oxygen can improve analysis and diagnosis of various diseases, such as neurological diseases and cancer [180–182]. An efficient method for the measurement of oxygen is based on oxygendependent quenching of metalloporphyrin phosphorescence. Platinum (Pt) and palladium (Pd) complex of porphyrin are suitable chromophores for oxygen dependent phosphorescence measurements due to their long lifetime and high quantum yield. Borisov et al. synthesized a series of Pt or Pd azatetrabenzoporphyrins (PtNTBP or PdNTBP) complex as oxygen indicators and PtNTBP showed spectral compatibility with 633 nm line of the He–Ne laser and the red laser diodes [183].

Optical PEBBLE (probes encapsulated by biologically localized embedding) nanosensors have been designed for dissolved oxygen in live cells [184]. Oxygen-sensitive Pt porphyrins, Pt(II) octaethylporphine and Pt(II) octaethylporphine ketone, were used as the indicator and incorporated in ormosil nanoparticles 120 nm in size. Oxygen-insensitive dyes, 3,3'-dioctadecyloxacarbocyanine perchlorate and octaethylporphine, were chosen as reference dyes respectively. The oxygen-indicators and reference dyes were entrapped during the formation process of the ormosil particles via a sol-gel-based process. The Pt-porphyrin PEBBLE nanosensor showed 97% overall quenching response over the whole range of dissolved oxygen concentrations (0-43 ppm, saturated) indicating excellent sensitivity to the oxygen. In additional, the PEBBLE nanosensor exhibited a good reversibility and complete recovery at each time the environment changed between saturated N₂ to saturated O₂. The PEBBLE nanosensors were delivered to rat C6 glioma cells by gene gun and successfully achieved real-time measurement of the intracellular dissolved oxygen concentration.

Methodologies have been developed for assessment of local oxygen gradients via a panel of oxygen-sensitive probes. Three phosphorescent Pt-porphyrin probes targeted to the cell membrane (Per-NP) [185], MitoXpress [186] and Nano2 probes [187], were developed to monitor the pericellular (PC), extracellular (EC), and intracellular (IC) O₂ concentrations, respectively. MitoXpress was based on Pt(II)-coproporphyrin coupled albumin, Per-NP and Nano2 probes were Eudragit RL-100 based nanoparticles loaded with Pt(II)-tetrakis(pentafluorophenyl)porphyrin (PtPFPP) (Fig. 25A). Per-NP probes contained ER9Q-PtCP, a recombinant fluorescent protein that could target the cell membrane, to measure the PC oxygen. The Nano2 probes (Fig. 25B) showed cellpenetration due to the interaction between positive charge on the RL-100 nanoparticle surface and the cell membrane which is negatively charged outside. These three Pt-porphyrin and phosphorescence lifetime-based oxygen probes showed sensitive and accurate measurement for the EC. PC and IC O₂ in different cell models (Fig. 25C). In addition, the magnitude of the measurement could be modulated by changing cell density or adjusting the specific activity of the cells. This panel of oxygen probes proved a simple and minimally invasive methodology for the investigate oxygen gradients in tissue culture.



Fig. 25. Oxygen responsive Pt-porphyrin probes. (A) The chemical structure of PtPFPP. (B) The (Left) SEM and (Right) AFM images of the PtPFPP-RL100 NPs. C) Phosphorescence lifetime (τ) calibrations for three probes obtained with non-respiring MEF cells. ER9Q-PtCP, MitoXpress and Nano2 were design for monitoring the pericellular (PC), extracellular (EC), and intracellular (IC) O₂ concentrations, respectively. Permission obtained from Ref. [185]. Copyright (2012) by American Chemical Society.



Fig. 26. Performance of a MM2 probe for sensing and imaging of icO2. (A) Phosphorescence lifetime calibration and Stern-Volmer plots of MM2 probe. (B) Widefield fluorescence lifetime microscopy images of MEF cells stained with MM2 (10 μ g mL⁻¹, 16 h). The images for different concentration of atmospheric O₂ were displayed. Permission obtained from Ref. [189] Copyright (2012) by Wiley.

To image the intracellular oxygen in 3D with submicron spatial resolution, Brinas et al. reported the design of a nanosensor for oxygen by combining phosphorescence quenching and two-photon absorption (2PA) [188]. Via intramolecular energy transfer (ET), the 2PA antenna induced phosphorescence of the metalloporphyrin and the signal was amplified. Oxygen-sensitive Pt-porphyrin was selected as the central phosphorescent indicator due to the strong triplet state emission. The construct of the coupled Pt-porphyrin and 2PA antenna chromophores was entrapped in shielding dendrimers where the chromophores were packed in a high density resulting in a more effective molecular 2PA cross-section. To achieve the proposed design, several Pt porphyrin-coumarin based oxygen sensors were synthesized and analyzed. The results demonstrated the feasibility of the oxygen measurements by combining two-photon microscopy and Pt-porphyrin based phosphorescent dyes.

Based on the Nano2 intracellular oxygen (icO₂) probes, the Papkovsky group designed multimodal icO₂ probes (MM series) allowing for ratiometric or multi-photon imaging of icO₂ [189]. MM probes were composed of an O₂ sensitive phosphor, PtPFPP; an O2-insensitive reference fluorophore as an antennae and FRET donor for PtTFPP, and the coating matrix cationic polymer RL-100 that formed the nanoparticle carrier for the encapsulation and delivery. For the reference antennae, the hydrophobic polymeric fluorophore, PFO showed better performance than C545T which leaked out from the nanoparticles during cell loading and internalization. The O₂ calibration for MM2 probe loaded in MEF cells showed a lifetime range from 28 to 61 μ s (Fig. 26A). MM2 probes could provide for high resolution imaging of the cellular O₂ based on ratiometric intensities and phosphorescence lifetime-based sensing under one- and two-photon excitation (Fig. 26B).

4. Conclusions

Metalloporphyrins are key to fundamental bioprocesses required for life on earth. Increasingly, metalloporphyrins are being assessed in biomedical fields. They are inherently suited for applications in theranostics due to their behavior as photoactive compounds for phototherapies and their utility for imaging with MRI, PET and optical modalities.

The central metals in the metalloporphyrins can enable axial coordination for other ligands, extending the diversity of metalloporphyrin nanomaterials. Metalloporphyrin nanoparticles can be modified with various functional groups via axial coordination following nanoparticle formation. Likewise, porphyrin nanoparticles could be modified with various metals following nanoparticle formation to impart diverse functions from a single batch of nanoparticles.

Much work remains to better understand and characterize both existing and new modular functions for metalloporphyrin nanoparticles. Likewise, more compelling applications need to be demonstrated. However, it is clear that porphyrin nanoparticles represent a promising platform for developing theranostic functions and metal chelation is central to these functions.

Acknowledgements

This work was supported by the National Institutes of Health (R01EB017270, DP5OD017898), the National Science Foundation (1555220) and the Government of India UGC-Raman Fellowship (5-104/2016 IC).

References

- [1] Y. Zhang, J.F. Lovell, Theranostics 2 (2012) 905–915.
- [2] H. Huang, W. Song, J. Rieffel, J.F. Lovell, Front. Phys. 3 (2015).
- [3] Y. Zhang, J.F. Lovell, Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 9 (2017) e1420-n/a. https://doi.org/10.1002/wnan.1420. [4] L.B. Josefsen, R.W. Boyle, Theranostics 2 (2012) 916–966.
- [5] Y. Zhou, X. Liang, Z. Dai, Nanoscale 8 (2016) 12394-12405.
- [6] M. Klingenberg, Arch. Biochem. Biophys. 75 (1958) 376-386.
- [7] T. Omura, J. Biol. Chem. 239 (1964) 2370-2378.
- [8] A.Y. Lu, M.J. Coon, J. Biol. Chem. 243 (1968) 1331-1332.
- [9] T.L. Poulos, Chem. Rev. 114 (2014) 3919.
- [10] N.R. Baker, Annu. Rev. Plant Biol. 59 (2008) 89-113. [11] A. Melis, Plant Sci. 177 (2009) 272-280.
- 12] C. Wu, Z. Niu, Q. Tang, W. Huang, Agric. For. Meteorol. 148 (2008) 1230–1241. [13] S.A. Henson, J.L. Sarmiento, J.P. Dunne, L. Bopp, I.D. Lima, S.C. Doney, J.G. John,
- C. Beaulieu, Biogeosci. 7 (2010) 621-640.
- [14] D.K. Dror, L.H. Allen, Nutr. Rev. 66 (2008) 250-255.
- [15] C. Yajnik, S. Deshpande, A. Jackson, H. Refsum, S. Rao, D. Fisher, D. Bhat, S. Naik, K. Coyaji, C. Joglekar, Diabetologia 51 (2008) 29-38.
- [16] L.H. Allen, Am. J. Clin. Nutr. 89 (2009) 693S-696S.
- R. Hu, Eur. J. Gen. Med. 12 (2015).
- [18] R.K. Thauer, A.-K. Kaster, H. Seedorf, W. Buckel, R. Hedderich, Nat. Rev. Microbiol. 6 (2008) 579–591.
- [19] K. Zheng, P.D. Ngo, V.L. Owens, X.-P. Yang, S.O. Mansoorabadi, Science 354 (2016) 339-342.
- [20] I. Willner, B. Willner, Nano Lett. 10 (2010) 3805-3815.
- [21] R. Subbiah, M. Veerapandian, K.S. Yun, Curr. Med. Chem. 17 (2010) 4559-4577.
- [22] K.E. Sapsford, W.R. Algar, L. Berti, K.B. Gemmill, B.J. Casey, E. Oh, M.H. Stewart, I.L. Medintz, Chem. Rev. 113 (2013) 1904-2074.
- [23] H. Huang, J.F. Lovell, Adv. Funct. Mater. 27 (2017), 1603524-n/a.
- [24] P. Couvreur, Adv. Drug Del. Rev. 65 (2013) 21-23.
- [25] D. Luo, K.A. Carter, J.F. Lovell, Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 7 (2015) 169-188. https://doi.org/10.1002/wnan. 1315.
- [26] S. Acharya, S.K. Sahoo, Adv. Drug Del. Rev. 63 (2011) 170-183.
- [27] V. Torchilin, Adv. Drug Del. Rev. 63 (2011) 131-135.
- [28] J. Fang, H. Nakamura, H. Maeda, Adv. Drug Del. Rev. 63 (2011) 136-151.
- [29] H. Maeda, H. Nakamura, J. Fang, Adv. Drug Del. Rev. 65 (2013) 71-79.

- [30] S. Mura, J. Nicolas, P. Couvreur, Nat. Mat. 12 (2013) 991-1003.
- [31] B.S. Pattni, V.V. Chupin, V.P. Torchilin, Chem. Rev. 115 (2015) 10938-10966. [32] R. Cheng, F. Meng, C. Deng, H.-A. Klok, Z. Zhong, Biomaterials 34 (2013) 3647-3657.
- [33] J. Kreuter, Adv. Drug Del. Rev. 71 (2014) 2-14.
- [34] K.E. Sapsford, K.M. Tyner, B.J. Dair, J.R. Deschamps, I.L. Medintz, Anal. Chem. 83 (2011) 4453-4488.
- [35] K.M. Kadish, K.M. Smith, R. Guilard, The Porphyrin Handbook: Inorganic, organometallic and coordination chemistry, Elsevier, 2000.
- [36] K.M. Kadish, K.M. Smith, R. Guilard, World Sci.: Singapore 2014 (2010) 1-35
- [37] F.H. Figge, G.S. Weiland, L.O. Manganiello, Proc. Soc. Exp. Biol. Med. 68 (1948) 640-641.
- [38] P.A. Waghorn, J. Labelled Comp. Radiopharm. 57 (2014) 304-309.
- [39] K.M. Smith, Porphyrins and Metalloporphyrins, Elsevier Amsterdam, 1975.
- [40] R. Williams, Chem. Rev. 56 (1956) 299-328.
- [41] L. Cuesta, J.L. Sessler, Chem. Soc. Rev. 38 (2009) 2716-2729.
- [42] W.R. Scheidt, Acc. Chem. Res. 10 (1977) 339-345.
- [43] E.B. Fleischer, Acc. Chem. Res. 3 (1970) 105-112.
- [44] D. Dolphin, The Porphyrins, vol. 1, Academic Press, New York, 1979.
- [45] P.J. Brothers, J. Porphyr. Phthalocya. 6 (2002) 259-267.
- [46] X. Gong, T. Milic, C. Xu, J.D. Batteas, C.M. Drain, J. Am. Chem. Soc. 124 (2002) 14290-14291.
- [47] C.M. Drain, G. Smeureanu, S. Patel, X. Gong, J. Garno, J. Arijeloye, New J. Chem. 30 (2006) 1834-1843.
- [48] L.Q. Xu, J.C. Chen, S.S. Qian, A.K. Zhang, G.D. Fu, C.M. Li, E.T. Kang, Macromol. Chem. Phys. 216 (2015) 417-426.
- [49] T. Poursaberi, M. Hassanisadi, K. Torkestani, M. Zare, Chem. Eng. J. 189 (2012) 117-125.
- [50] X. Liang, X. Li, L. Jing, X. Yue, Z. Dai, Biomaterials 35 (2014) 6379-6388.
- [51] X. Yao, L. Chen, X. Chen, Z. Xie, J. Ding, C. He, J. Zhang, X. Chen, Acta Biomater.
- 25 (2015) 162–171. [52] M. Ince, A. Hausmann, M.V. Martínez-Díaz, D.M. Guldi, T. Torres, Chem. Commun. 48 (2012) 4058–4060.
- [53] V. Mamaeva, C. Sahlgren, M. Lindén, Adv. Drug Del. Rev. 65 (2013) 689-702. [54] E. Huynh, G. Zheng, Nano Today 9 (2014) 212-222.
- [55] J.F. Lovell, C.S. Jin, E. Huynh, H. Jin, C. Kim, J.L. Rubinstein, W.C. Chan, W. Cao,
- L.V. Wang, G. Zheng, Nat. Mater. 10 (2011) 324-332.
- [56] J.F. Lovell, C.S. Jin, E. Huynh, T.D. MacDonald, W. Cao, G. Zheng, Angew. Chem. Int. Ed. 51 (2012) 2429-2433.
- [57] W.-S. Li, T. Aida, Chem. Rev. 109 (2009) 6047-6076.
- [58] N. Nishiyama, W.-D. Jang, K. Kataoka, New J. Chem. 31 (2007) 1074-1082.
- [59] W. Hinshaw, P.A. Bottomley, G. Holland, Nature 270 (1977) 722-723.
- [60] M. Aschner, T.R. Guilarte, J.S. Schneider, W. Zheng, Toxicol. Appl. Pharmacol. 221 (2007) 131–147.
- [61] D.J. Todd, J. Kay, Annu. Rev. Med. 67 (2016) 273-291.
- [62] M. Punnagai, B. Sateesh, G.N. Sastry, ARKIVOC 3 (2005) 258–283.
- [63] A. Tulinsky, B.M. Chen, J. Am. Chem. Soc. 99 (1977) 3647–3651. [64] P. Caravan, J.J. Ellison, T.J. McMurry, R.B. Lauffer, Chem. Rev. 99 (1999) 2293-
- 2352 [65] M.J.F. Calvete, S.M.A. Pinto, M.M. Pereira, C.F.G.C. Geraldes, Coord. Chem. Rev.
- 333 (2017) 82-107.
- [66] S. Aime, M. Botta, E. Gianolio, E. Terreno, Angew. Chem. 112 (2000) 763-766.
- [67] Y. Takehara, H. Sakahara, H. Masunaga, S. Isogai, N. Kodaira, M. Sugiyama, H. Takeda, T. Saga, S. Nakajima, I. Sakata, Magn. Reson. Med. 47 (2002) 549-553.
- [68] X.-A. Zhang, K.S. Lovejoy, A. Jasanoff, S.J. Lippard, Proc. Nat. Acad. Sci. 104 (2007) 10780-10785.
- [69] Z. Zhang, R. He, K. Yan, Q.-N. Guo, Y.-G. Lu, X.-X. Wang, H. Lei, Z.-Y. Li, Bioorg. Med. Chem. Lett. 19 (2009) 6675-6678.
- [70] D. Pan, S.D. Caruthers, G. Hu, A. Senpan, M.J. Scott, P.J. Gaffney, S.A. Wickline, G.M. Lanza, J. Am. Chem. Soc. 130 (2008) 9186-9187.
- [71] L. Jing, X. Liang, X. Li, Y. Yang, Z. Dai, Acta Biomater. 9 (2013) 9434–9441.
- [72] L. Jing, X. Liang, X. Li, L. Lin, Y. Yang, X. Yue, Z. Dai, Theranostics 4 (2014) 858. [73] T. Zou, M. Zhen, D. Chen, R. Li, M. Guan, C. Shu, H. Han, C. Wang, Dalton Trans.
- 44 (2015) 9114-9119. [74] T.D. MacDonald, T.W. Liu, G. Zheng, Angew. Chem. Int. Ed. 53 (2014) 6956-
- 6959. [75] I.M. Keca, J. Chen, M. Overchuk, N. Muhanna, C.M. MacLaughlin, C.S. Jin, W.D. Foltz, J.C. Irish, G. Zheng, Angew. Chem. 128 (2016) 6295-6299.
- [76] S. Shao, T.N. Do, A. Razi, U. Chitgupi, J. Geng, R.J. Alsop, B.G. Dzikovski, M.C. Rheinstädter, J. Ortega, M. Karttunen, Small 13 (2017).
- [77] M. Ethirajan, Y. Chen, P. Joshi, R.K. Pandey, Chem. Soc. Rev. 40 (2011) 340-362.
- [78] K.A. Carter, S. Shao, M.I. Hoopes, D. Luo, B. Ahsan, V.M. Grigoryants, W. Song, H. Huang, G. Zhang, R.K. Pandey, Nat. Commun. 5 (2014) 3546.
- [79] K.A. Carter, D. Luo, A. Razi, J. Geng, S. Shao, J. Ortega, J.F. Lovell, Theranostics 6 (2016) 2329.
- [80] J. Kress, D.J. Rohrbach, K.A. Carter, D. Luo, S. Shao, S. Lele, J.F. Lovell, U. Sunar, Biomed. Opt. Express 6 (2015) 3546-3555.
- [81] D. Luo, K.A. Carter, A. Razi, J. Geng, S. Shao, D. Giraldo, U. Sunar, J. Ortega, J.F. Lovell, Biomaterials 75 (2016) 193-202.
- [82] D. Luo, K.A. Carter, A. Razi, J. Geng, S. Shao, C. Lin, J. Ortega, J.F. Lovell, J. Control. Release 220 (2015) 484-494.
- [83] D. Luo, N. Li, K.A. Carter, C. Lin, J. Geng, S. Shao, W.C. Huang, Y. Qin, G.E. Atilla-Gokcumen, J.F. Lovell, Small 12 (2016) 3039–3047.

- [84] U. Sunar, J. Kress, D.J. Rohrbach, K. Carter, D. Luo, S. Shao, S. Lele, J.F. Lovell, Cancer Imaging Ther. (2016), JW4A.
- [85] T. Jahanbin, H. Sauriat-Dorizon, P. Spearman, S. Benderbous, H. Korri-Youssoufi, Mat. Sci. Eng. C 52 (2015) 325-332.
- [86] H. Gong, Z. Dong, Y. Liu, S. Yin, L. Cheng, W. Xi, J. Xiang, K. Liu, Y. Li, Z. Liu, Adv. Funct. Mater. 24 (2014) 6492-6502.
- [87] J. Rieffel, U. Chitgupi, J.F. Lovell, Small 11 (2015) 4445-4461.
- [88] D.-E. Lee, H. Koo, I.-C. Sun, J.H. Ryu, K. Kim, I.C. Kwon, Chem. Soc. Rev. 41 (2012) 2656-2672.
- [89] X. Liang, Y. Li, X. Li, L. Jing, Z. Deng, X. Yue, C. Li, Z. Dai, Adv. Funct. Mater. 25 (2015) 1451-1462.
- S.W. Young, M.K. Sidhu, F. Qing, H.H. Muller, M. Neuder, G. Zanassi, T.D. [90] Mody, G. Hemmi, W. Dow, J.D. Mutch, J.L. Sessler, R.A. Miller, Invest. Radiol. 29 (1994) 330-338.
- [91] S.W. Young, F. Qing, A. Harriman, J.L. Sessler, W.C. Dow, T.D. Mody, G.W. Hemmi, Y. Hao, R.A. Miller, Proc. Nat. Acad. Sci. 93 (1996) 6610-6615.
- [92] J.L. Sessler, T.D. Mody, G.W. Hemmi, V. Lynch, S.W. Young, R.A. Miller, J. Am. Chem. Soc. 115 (1993) 10368-10369.
- [93] N.M. Barkey, C. Preihs, H.H. Cornnell, G. Martinez, A. Carie, J. Vagner, L. Xu, M. C. Lloyd, V.M. Lynch, V.J. Hruby, J. Med. Chem. 56 (2013) 6330-6338.
- [94] M.H. Lee, E.-J. Kim, H. Lee, H.M. Kim, M.J. Chang, S.Y. Park, K.S. Hong, J.S. Kim, J. L. Sessler, J. Am. Chem. Soc. 138 (2016) 16380-16387.
- [95] H.-J. Yoon, T.G. Lim, J.-H. Kim, Y.M. Cho, Y.S. Kim, U.S. Chung, J.H. Kim, B.W. Choi, W.-G. Koh, W.-D. Jang, Biomacromolecules 15 (2014) 1382-1389.
- [96] J.P. Mbakidi, F. Brégier, T.S. Ouk, R. Granet, S. Alves, E. Rivière, S. Chevreux, G. Lemercier, V. Sol, ChemPlusChem 80 (2015) 1416-1426.
- [97] J. Boudon, J. Paris, Y. Bernhard, E. Popova, R.A. Decréau, N. Millot, Chem. Commun. 49 (2013) 7394–7396.
- [98] S.-H. Xuan, S.-F. Lee, J.T.-F. Lau, X. Zhu, Y.-X.J. Wang, F. Wang, J.M. Lai, K.W. Sham, P.-C. Lo, J.C. Yu, ACS Appl. Mater. Inter. 4 (2012) 2033-2040.
- [99] D.W. Townsend, T. Beyer, T.M. Blodgett, Semin. Nucl. Med., Elsevier, 2003, pp. 193-204.
- [100] P.H. Elsinga, Nucl. Med. Rev. 15 (2012) 13-16.
- [101] H. Ali, J.E. van Lier, Chem. Rev. 99 (1999) 2379-2450.
- [102] S. Sadeghi, M. Mirzaei, M. Rahimi, A.R. Jalilian, Asia Oceania J. Nucl. Med. Biol.
- 2 (2014) 95–103. [103] J.-H. Lee, S. Shao, K.T. Cheng, J.F. Lovell, C.H. Paik, J. Liposome Res. 25 (2015) 101-106.
- [104] P.A. Waghorn, J. Labelled Compounds Radiopharm. 57 (2014) 304-309.
- [105] A. Srivatsan, J.R. Missert, S.K. Upadhyay, R.K. Pandey, J. Porphyr. Phthalocya. 19 (2015) 109–134.
- [106] F.R. Wrenn, M.L. Good, P. Handler, Science 113 (1951) 525-527.
- [107] P.J. Blower, J.S. Lewis, J. Zweit, Nucl. Med. Biol. 23 (1996) 957-980.
- [108] W.P. Jeeves, B.C. Wilson, G. Firnau, K. Brown, Studies of HPD and radiolabelled HPD in-vivo and in-vitro, in: Methods in Porphyrin Photosensitization, Springer, 1985, pp. 51-67.
- [109] B.C. Wilson, G. Firnau, W.P. Jeeves, K.L. Brown, D.M. Burns-McCormick, Lasers Med. Sci. 3 (1988) 71-80.
- [110] J. Shi, T. Liu, J. Chen, D. Green, D. Jaffray, B.C. Wilson, F. Wang, G. Zheng, Theranostics 1 (2011) 363-370.
- [111] T.W. Liu, T.D. MacDonald, J. Shi, B.C. Wilson, G. Zheng, Angew. Chem. Int. Ed. 51 (2012) 13128-13131.
- [112] T.W. Liu, T.D. MacDonald, C.S. Jin, J.M. Gold, R.G. Bristow, B.C. Wilson, G. Zheng, ACS Nano 7 (2013) 4221-4232.
- [113] J. Rieffel, F. Chen, J. Kim, G. Chen, W. Shao, S. Shao, U. Chitgupi, R. Hernandez, S.A. Graves, R.J. Nickles, Adv. Mater. 27 (2015) 1785–1790. [114] H. Huang, R. Hernandez, J. Geng, H. Sun, W. Song, F. Chen, S.A. Graves, R.J.
- Nickles, C. Cheng, W. Cai, Biomaterials 76 (2016) 25-32.
- [115] Y. Zhang, D. Wang, S. Goel, B. Sun, U. Chitgupi, J. Geng, H. Sun, T.E. Barnhart, W. Cai, J. Xia, Adv. Mater. 28 (2016) 8524-8530.
- [116] Y. Zhang, M. Jeon, L.J. Rich, H. Hong, J. Geng, Y. Zhang, S. Shi, T.E. Barnhart, P. Alexandridis, J.D. Huizinga, M. Seshadri, W. Cai, C. Kim, J.F. Lovell, Nat. Nanotechnol. 9 (2014) 631-638.
- [117] Y. Li, T.-Y. Lin, Y. Luo, Q. Liu, W. Xiao, W. Guo, D. Lac, H. Zhang, C. Feng, S. Wachsmann-Hogiu, J.H. Walton, S.R. Cherry, D.J. Rowland, D. Kukis, C. Pan, K. S. Lam, Nat. Commun. 5 (2014).
- [118] L. Feng, L. Cheng, Z. Dong, D. Tao, T.E. Barnhart, W. Cai, M. Chen, Z. Liu, ACS Nano (2016).
- [119] J. Kneipp, H. Kneipp, K. Kneipp, Chem. Soc. Rev. 37 (2008) 1052-1060.
- [120] X. Qian, X.-H. Peng, D.O. Ansari, Q. Yin-Goen, G.Z. Chen, D.M. Shin, L. Yang, A. N. Young, M.D. Wang, S. Nie, Nat. Biotechnol. 26 (2008) 83-90.
- [121] M. Hamer, I.N. Rezzano, Inorg. Chem. 55 (2016) 8595–8602.
- [122] L.M. Ferreira, D. Grasseschi, M.S. Santos, P.R. Martins, I.G. Gutz, A.M.C. Ferreira, K. Araki, H.E. Toma, L.C. Angnes, Langmuir 31 (2015) 4351–4360.
- [123] S. Murphy, L. Huang, P.V. Kamat, J. Phys. Chem. C 115 (2011) 22761-22769. [124] N.C. Tam, B.M. Scott, D. Voicu, B.C. Wilson, G. Zheng, Bioconjug. Chem. 21
- (2010) 2178-2182. [125] N.C. Tam, P.Z. McVeigh, T.D. MacDonald, A. Farhadi, B.C. Wilson, G. Zheng,
- Bioconjug. Chem. 23 (2012) 1726-1730.
- [126] A. Farhadi, Á. Roxin, B.C. Wilson, G. Zheng, Theranostics 5 (2015) 469.
- [127] A. Abuteen, S. Zanganeh, J. Akhigbe, L.P. Samankumara, A. Aguirre, N. Biswal, M. Braune, A. Vollertsen, B. Röder, C. Brückner, Phys. Chem. Chem. Phys. 15 (2013) 18502-18509.
- [128] E. Huynh, C.S. Jin, B.C. Wilson, G. Zheng, Bioconjug. Chem. 25 (2014) 796–801.
- [129] K.K. Ng, M. Takada, K. Harmatys, J. Chen, G. Zheng, ACS Nano 10 (2016) 4092-4101.

- [130] M. Yu, F. Li, Z. Chen, H. Hu, C. Zhan, H. Yang, C. Huang, Anal. Chem. 81 (2009) 930–935.
- [131] T. Yang, Y. Sun, Q. Liu, W. Feng, P. Yang, F. Li, Biomaterials 33 (2012) 3733– 3742.
- [132] G. Chen, J. Shen, T.Y. Ohulchanskyy, N.J. Patel, A. Kutikov, Z. Li, J. Song, R.K. Pandey, H. Ågren, P.N. Prasad, ACS Nano 6 (2012) 8280–8287.
- [133] T.N. Singh-Rachford, A. Haefele, R. Ziessel, F.N. Castellano, J. Am. Chem. Soc. 130 (2008) 16164–16165.
- [134] Q. Liu, T. Yang, W. Feng, F. Li, J. Am. Chem. Soc. 134 (2012) 5390-5397.
- [135] Q. Liu, B. Yin, T. Yang, Y. Yang, Z. Shen, P. Yao, F. Li, J. Am. Chem. Soc. 135 (2013) 5029–5037.
- [136] M. Hayyan, M.A. Hashim, I.M. AlNashef, Chem. Rev. 116 (2016) 3029-3085.
- [137] D.E. Dolmans, D. Fukumura, R.K. Jain, Nat. Rev. Cancer 3 (2003) 380-387.
- [138] S.B. Brown, E.A. Brown, I. Walker, Lancet Oncol. 5 (2004) 497–508.
- [139] V.J. Pansare, S. Hejazi, W.J. Faenza, R.K. Prud'homme, Chem. Mater. 24 (2012) 812-827.
- [140] A. Harriman, Faraday Trans. 1 (76) (1980) 1978–1985.
- [141] L.D. Lavis, R.T. Raines, ACS Chem. Biol. 3 (2008) 142-155.
- [142] T. Nyokong, Coord. Chem. Rev. 251 (2007) 1707–1722.
- [143] A. Harriman, J. Chem. Soc. Faraday Trans. 2 (77) (1981) 1281-1291.
- [144] K.A. Carter, S. Wang, J. Geng, D. Luo, S. Shao, J.F. Lovell, Mol. Pharm. 13 (2015) 420-427.
- [145] E. Ricci-Júnior, J.M. Marchetti, Int. J. Pharm. 310 (2006) 187-195.
- [146] X. Yao, X. Chen, C. He, L. Chen, X. Chen, J. Mater. Chem. B 3 (2015) 4707–4714.
- [147] D. Luo, K.A. Carter, D. Miranda, J.F. Lovell, Adv. Sci. 4 (2017), 1600106-n/a.
- [148] N. Sekkat, H.V.d. Bergh, T. Nyokong, N. Lange, Molecules 17 (2012) 98.
- [149] L.A. Muehlmann, B.C. Ma, J.P.F. Longo, M.d.F.M.A. Santos, R.B. Azevedo, Int. J. Nanomed. 9 (2014) 1199.
- [150] P. Zhang, W. Steelant, M. Kumar, M. Scholfield, J. Am. Chem. Soc. 129 (2007) 4526–4527.
- (151) F. Wang, X. Chen, Z. Zhao, S. Tang, X. Huang, C. Lin, C. Cai, N. Zheng, J. Mater. Chem. 21 (2011) 11244–11252.
- [152] Z. Zhao, Y. Han, C. Lin, D. Hu, F. Wang, X. Chen, Z. Chen, N. Zheng, Chem. Asian I, 7 (2012) 830–837.
- [153] S. Cui, D. Yin, Y. Chen, Y. Di, H. Chen, Y. Ma, S. Achilefu, Y. Gu, ACS Nano 7 (2012) 676–688.
- [154] J.T. Lau, P.-C. Lo, X.-J. Jiang, Q. Wang, D.K. Ng, J. Med. Chem. 57 (2014) 4088– 4097.
- [155] S. Shao, J. Geng, H.A. Yi, S. Gogia, S. Neelamegham, A. Jacobs, J.F. Lovell, Nat. Chem. 7 (2015) 438–446.
- [156] Y. Li, A. Hill, M. Beitelshees, S. Shao, J.F. Lovell, B.A. Davidson, P.R. Knight, A.P. Hakansson, B.A. Pfeifer, C.H. Jones, Proc. Natl. Acad. Sci. 113 (2016) 6898– 6903.
- [157] M.E. El-Khouly, O. Ito, P.M. Smith, F. D'Souza, J. Photochem. Photobiol. C 5 (2004) 79–104.
- [158] D.V. Konarev, S.S. Khasanov, R.N. Lyubovskaya, Coord. Chem. Rev. 262 (2014) 16–36.
- [159] M.A. Lebedeva, T.W. Chamberlain, A.N. Khlobystov, Chem. Rev. 115 (2015) 11301–11351.
- [160] T. Ishii, N. Aizawa, R. Kanehama, M. Yamashita, K.-I. Sugiura, H. Miyasaka, Coord. Chem. Rev. 226 (2002) 113–124.
- [161] D.V. Konarev, S.S. Khasanov, Á. Otsuka, G. Saito, R.N. Lyubovskaya, Chem. Eur. J. 12 (2006) 5225–5230.

- [162] M.M. Olmstead, D.A. Costa, K. Maitra, B.C. Noll, S.L. Phillips, P.M. Van Calcar, A.L. Balch, J. Am. Chem. Soc. 121 (1999) 7090–7097.
- [163] P.D. Boyd, M.C. Hodgson, C.E. Rickard, A.G. Oliver, L. Chaker, P.J. Brothers, R.D. Bolskar, F.S. Tham, C.A. Reed, J. Am. Chem. Soc. 121 (1999) 10487–10495.
- [164] D.V. Konarev, S.S. Khasanov, M.A. Faraonov, R.N. Lyubovskaya, CrystEngComm 14 (2012) 4350–4356.
- [165] D.V. Konarev, S.S. Khasanov, A. Otsuka, Y. Yoshida, G. Saito, J. Am. Chem. Soc. 124 (2002) 7648–7649.
- [166] D.V. Konarev, S.S. Khasanov, G. Saito, R.N. Lyubovskaya, Y. Yoshida, A. Otsuka, Chem. Eur. J. 9 (2003) 3837–3848.
- [167] D.V. Konarev, S.S. Khasanov, A. Otsuka, G. Saito, R.N. Lyubovskaya, Dalton Trans. (2009) 6416–6420.
- [168] D.V. Konarev, S.S. Khasanov, A.B. Kornev, M.A. Faraonov, P.A. Troshin, R.N. Lyubovskaya, Dalton Trans. 41 (2012) 791–798.
- [169] L.-C. Song, X.-F. Liu, Z.-J. Xie, F.-X. Luo, H.-B. Song, Inorg. Chem. 50 (2011) 11162–11172.
- [170] T. Ohse, S. Nagaoka, Y. Arakawa, H. Kawakami, K. Nakamura, J. Inorg. Biochem. 85 (2001) 201–208.
- [171] N. Kasugai, T. Murase, T. Ohse, S. Nagaoka, H. Kawakami, S. Kubota, J. Inorg. Biochem. 91 (2002) 349–355.
- [172] H. Kawakami, K. Hiraka, M. Tamai, A. Horiuchi, A. Ogata, T. Hatsugai, A. Yamaguchi, K. Oyaizu, M. Yuasa, Polym. Adv. Technol. 18 (2007) 82–87.
- [173] K. Hiraka, M. Kanehisa, M. Tamai, S. Asayama, S. Nagaoka, K. Oyaizu, M. Yuasa, H. Kawakami, Colloids Surf. B. Biointerfaces 67 (2008) 54–58.
- [174] M. Yuasa, K. Oyaizu, A. Horiuchi, A. Ogata, T. Hatsugai, A. Yamaguchi, H. Kawakami, Mol. Pharm. 1 (2004) 387–389.
- [175] H. Umakoshi, K. Morimoto, Y. Ohama, H. Nagami, T. Shimanouchi, R. Kuboi, Langmuir 24 (2008) 4451–4455.
- [176] M. Kanehisa, S. Asayama, H. Kawakami, Desalin. Water Treat. 17 (2010) 31– 36.
- [177] T. Aikawa, S. Ito, M. Shinohara, M. Kaneko, T. Kondo, M. Yuasa, Biomater. Sci. 3 (2015) 861–869.
- [178] H. Lee, K.-I. Hong, W.-D. Jang, Coord. Chem. Rev. 354 (2018) 46-73.
- [179] H. Huang, S. Chauhan, J. Geng, Y. Qin, D.F. Watson, J.F. Lovell, Biomacromolecules 18 (2017) 562–567.
- [180] T. Hagen, C.T. Taylor, F. Lam, S. Moncada, Science 302 (2003) 1975–1978.
- [181] A.Y. Abramov, A. Scorziello, M.R. Duchen, J. Neurosci. 27 (2007) 1129–1138.
- [182] S.M. Evans, C.J. Koch, Cancer Lett. 195 (2003) 1-16.
- [183] S.M. Borisov, G. Zenkl, I. Klimant, ACS Appl. Mater. Inter. 2 (2010) 366–374.
- [184] Y.-E.L. Koo, Y. Cao, R. Kopelman, S.M. Koo, M. Brasuel, M.A. Philbert, Anal. Chem. 76 (2004) 2498–2505.
- [185] R.I. Dmitriev, A.V. Zhdanov, G. Jasionek, D.B. Papkovsky, Anal. Chem. 84 (2012) 2930–2938.
- [186] T.C. O'Riordan, A.V. Zhdanov, G.V. Ponomarev, D.B. Papkovsky, Anal. Chem. 79 (2007) 9414–9419.
- [187] A. Fercher, S.M. Borisov, A.V. Zhdanov, I. Klimant, D.B. Papkovsky, ACS Nano 5 (2011) 5499–5508.
- [188] R.P. Briñas, T. Troxler, R.M. Hochstrasser, S.A. Vinogradov, J. Am. Chem. Soc. 127 (2005) 11851.
- [189] A.V. Kondrashina, R.I. Dmitriev, S.M. Borisov, I. Klimant, I. O'Brien, Y.M. Nolan, A.V. Zhdanov, D.B. Papkovsky, Adv. Funct. Mater. 22 (2012) 4931–4939.